<SEC-DOCUMENT>0001193125-24-070139.txt : 20240318
<SEC-HEADER>0001193125-24-070139.hdr.sgml : 20240318
<ACCEPTANCE-DATETIME>20240318160817
ACCESSION NUMBER:		0001193125-24-070139
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20240318
DATE AS OF CHANGE:		20240318

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MADRIGAL PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0001157601
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-256666
		FILM NUMBER:		24759070

	BUSINESS ADDRESS:	
		STREET 1:		200 BARR HARBOR DRIVE, SUITE 400
		CITY:			WEST CONSHOHOCKEN
		STATE:			PA
		ZIP:			19428
		BUSINESS PHONE:		404-380-9263

	MAIL ADDRESS:	
		STREET 1:		200 BARR HARBOR DRIVE, SUITE 400
		CITY:			WEST CONSHOHOCKEN
		STATE:			PA
		ZIP:			19428

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SYNTA PHARMACEUTICALS CORP
		DATE OF NAME CHANGE:	20010815
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>d694036d424b5.htm
<DESCRIPTION>424B5
<TEXT>
<HTML><HEAD>
<TITLE>424B5</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Filed Pursuant to Rule 424(b)(5)<BR>Registration No. 333-256666 </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Arial Narrow"><FONT COLOR="#ff4338"><B>The information in this preliminary prospectus supplement is not
complete and may be changed. A registration statement relating to these securities has become effective by rule of the Securities and Exchange Commission. This preliminary prospectus supplement and the accompanying prospectus are not an offer to
sell these securities, and we are not soliciting offers to buy these securities, in any state or other jurisdiction where the offer or sale is not permitted. </B></FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#ff4338"><B>SUBJECT TO COMPLETION, DATED MARCH&nbsp;18, 2024 </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PRELIMINARY PROSPECTUS SUPPLEMENT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(to Prospectus dated
June&nbsp;1, 2021) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>$500,000,000 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g694036g01p01.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Shares of Common Stock </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants to Purchase &#8195;&#8195;&#8195;&#8195; Shares of Common Stock </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are offering &#8195;&#8195;&#8195; shares of our common stock and <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants to purchase
&#8195;&#8195;&#8195;shares of our common stock pursuant to this prospectus supplement and the accompanying prospectus. The purchase price of each <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant will equal the price per share at which
shares of common stock are being sold to the public in this offering, minus $&#8195;&#8195;&#8195;, which is the exercise price of each <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant. This prospectus supplement also relates to the
offering of the shares of common stock issuable upon exercise of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
common stock is listed on The Nasdaq Global Select Market under the symbol &#147;MDGL&#148;. On March&nbsp;15, 2024, the last reported sale price of our common stock on The Nasdaq Global Select Market was $270.37 per share. We do not intend to list
the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants on The Nasdaq Global Select Market, any other national securities exchange or any other nationally recognized trading system. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:12pt; font-family:Times New Roman"><B>Investing in our securities involves a high degree of risk. You should carefully consider the risks described under the heading &#147;<A HREF="#supptoc694036_4">Risk
 Factors</A>&#147; beginning on page <FONT STYLE="white-space:nowrap">S-12</FONT> of this prospectus supplement before buying shares of our securities. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="49%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per&nbsp;Share&nbsp;of<BR>Common&nbsp;Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per<BR><FONT STYLE="white-space:nowrap">Pre-Funded&nbsp;Warrant</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Underwriting discounts and commissions(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds, before expenses, to us</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">See &#147;Underwriting&#148; beginning on page <FONT STYLE="white-space:nowrap">S-25</FONT> of this prospectus
supplement for information regarding compensation payable to the underwriters. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have granted the underwriters an
option to purchase up to an additional &#8195;&#8195;&#8195; shares of our common stock from us at the public offering price, less the underwriting discounts and commissions payable by us. This option is exercisable, in whole or in part, for a
period of 30 days following the date of this prospectus supplement. If the underwriters exercise the option in full, the total underwriting discounts and commissions payable by us will be approximately $&#8195;&#8195;&#8195;, and the total proceeds
to us, before expenses, will be approximately $&#8195;&#8195;&#8195;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any state
securities commission has approved or disapproved of these securities or determined if this prospectus supplement or the accompanying prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters expect to deliver the securities to investors on or about March&#8195; , 2024. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:13.5pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:13.5pt">
<TD VALIGN="top"><B>Goldman&nbsp;Sachs&nbsp;&amp;&nbsp;Co.&nbsp;LLC</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Jefferies</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><B>TD&nbsp;Cowen</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>Evercore&nbsp;ISI</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>Piper&nbsp;Sandler</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" ALIGN="center">


<TR>

<TD WIDTH="25%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="58%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="15%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:6pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:12pt"><B>UBS&nbsp;Investment&nbsp;Bank</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="right"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:12pt; font-family:Times New Roman" ALIGN="right"><B>Citizens&nbsp;JMP</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of this prospectus supplement is March &#8195;, 2024 </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Page</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS SUPPLEMENT</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc694036_1">About This Prospectus Supplement</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">S-1</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc694036_2">Cautionary Note Regarding Forward-Looking Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">S-3</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc694036_3">Prospectus Supplement Summary</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">S-6</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc694036_4">Risk Factors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">S-12</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc694036_5">Use of Proceeds</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">S-16</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc694036_6">Dilution</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">S-17</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc694036_7">Description of <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants
</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">S-20</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc694036_8">Material U.S. Federal Income Tax Consequences to <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holders</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">S-21</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc694036_9">Underwriting</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">S-25</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc694036_10">Legal Matters</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">S-32</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc694036_11">Experts</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">S-32</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc694036_12">Where You Can Find More Information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">S-32</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc694036_13">Incorporation of Certain Information by Reference</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">S-32</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Page</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx694096_1">About This Prospectus</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx694096_2">Where You Can Find Additional Information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx694096_3">Incorporation of Certain Information by Reference</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx694096_4">Special Note Regarding Forward-Looking Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx694096_5">Risk Factors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx694096_6">About the Company</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx694096_7">Description of Securities to be Offered</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx694096_8">Use of Proceeds</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx694096_9">Selling Stockholders</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx694096_10">Plan of Distribution</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx694096_11">Legal Matters</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx694096_12">Experts</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc694036_1"></A>ABOUT THIS PROSPECTUS SUPPLEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This document is part of a registration statement that we filed with the Securities and Exchange Commission (&#147;SEC&#148;) using a
&#147;shelf&#148; registration process and consists of two parts. The first part is this prospectus supplement, including the documents incorporated by reference herein, which describes the specific terms of this offering. The second part, the
accompanying prospectus, including the documents incorporated by reference therein, provides more general information. In general, when we refer only to the prospectus, we are referring to both parts of this document combined. Before you invest, you
should carefully read this prospectus supplement, the accompanying prospectus, all information incorporated by reference herein and therein, as well as the additional information described under the heading &#147;Where You Can Find More
Information.&#148; These documents contain information you should carefully consider when deciding whether to invest in our securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus supplement may add, update or change information contained in the accompanying prospectus. To the extent there is a conflict
between the information contained in this prospectus supplement and the accompanying prospectus, you should rely on information contained in this prospectus supplement, provided that if any statement in, or incorporated by reference into, one of
these documents is inconsistent with a statement in another document having a later date, the statement in the document having the later date modifies or supersedes the earlier statement. Any statement so modified will be deemed to constitute a part
of this prospectus only as so modified, and any statement so superseded will be deemed not to constitute a part of this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You
should rely only on the information contained in this prospectus supplement, the accompanying prospectus, any document incorporated by reference herein or therein, or any free writing prospectuses we have authorized for use in connection with this
offering. Neither we nor the underwriters have authorized anyone to provide you with any different information. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may provide to
you. The information contained in this prospectus supplement, the accompanying prospectus, and in the documents incorporated by reference herein or therein is accurate only as of the date such information is presented. Our business, financial
condition, results of operations and prospects may have changed since those dates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus supplement and the accompanying
prospectus do not constitute, and may not be used in connection with, an offer to sell or the solicitation of an offer to buy any securities other than the shares of common stock and <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants to
which it relates, nor do this prospectus supplement and the accompanying prospectus constitute an offer to sell or the solicitation of an offer to buy securities in any jurisdiction to any person to whom it is unlawful to make such offer or
solicitation in such jurisdiction. Persons outside of the United States who come into possession of this prospectus supplement and the accompanying prospectus must inform themselves about, and observe any restrictions relating to, the offering of
the securities and the distribution of this prospectus supplement and the accompanying prospectus outside the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless
otherwise indicated, information contained in or incorporated by reference into this prospectus supplement concerning our industry and the markets in which we operate, including market opportunity, market position and competitive landscape, is based
on information from our management&#146;s estimates, as well as from industry publications, surveys and studies conducted by third parties. Management estimates are derived from publicly available information, our knowledge of our industry, and
assumptions based on such information and knowledge, which we believe to be reasonable. In addition, while we believe that information contained in the industry publications, surveys and studies has been obtained from reliable sources, the accuracy
and completeness of such information is not guaranteed, and we have not independently verified any of the data contained in these third-party sources. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus supplement and the accompanying prospectus, and any documents incorporated by reference herein or therein, include statements
that are based on various assumptions and estimates that are subject to numerous known and unknown risks and uncertainties. Some of these risks and uncertainties are described under the heading &#147;Risk Factors&#148; beginning on page <FONT
STYLE="white-space:nowrap">S-12</FONT> of this prospectus supplement and in the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
section titled &#147;Risk Factors&#148; in Part I, Item 1A of our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2023, filed with the SEC
on February&nbsp;28, 2024, which is incorporated by reference into the prospectus. These and other important factors could cause our future results to be materially different from the results expected as a result of, or implied by, these assumptions
and estimates. You should read the information contained in this prospectus supplement and the accompanying prospectus, and the documents incorporated by reference herein and therein, completely and with the understanding that future results may be
materially different and worse from what we expect. See the information included under the heading &#147;Cautionary Note Regarding Forward-Looking Statements.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We note that the representations, warranties and covenants made by us in any agreement that is filed as an exhibit to any document that is
incorporated by reference into this prospectus supplement or the accompanying prospectus were made solely for the benefit of the parties to such agreement, including, in some cases, for the purpose of allocating risk among the parties to such
agreement, and should not be deemed to be a representation, warranty or covenant to you. Moreover, such representations, warranties or covenants were accurate only as of the date when made. Accordingly, such representations, warranties and covenants
should not be relied on as accurately representing the current state of our affairs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated or the context otherwise
requires, the terms &#147;Company,&#148; &#147;Madrigal,&#148; &#147;Madrigal Pharmaceuticals,&#148; &#147;we,&#148; &#147;us&#148; and &#147;our&#148; refer to Madrigal Pharmaceuticals, Inc., a Delaware corporation, and its predecessors and
consolidated subsidiaries, and the term &#147;securities&#148; refers to shares of our common stock and our <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc694036_2"></A>CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus supplement, the accompanying prospectus and the documents we incorporate by reference herein and therein include
forward-looking statements within the meaning of the federal securities laws, which statements are: subject to substantial risks and uncertainties; based on our beliefs and assumptions and on information currently available to us; and subject to
factors beyond our control. These forward-looking statements are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are
forward-looking statements. Forward-looking statements reflect management&#146;s current knowledge, assumptions, judgment and expectations regarding forward-looking statements, future performance or events; include all statements that are not
historical facts; and can be identified by terms such as &#147;accelerate,&#148; &#147;achieve,&#148; &#147;allow,&#148; &#147;anticipates,&#148; &#147;appear,&#148; &#147;be,&#148; &#147;believes,&#148; &#147;can,&#148; &#147;continue,&#148;
&#147;could,&#148; &#147;demonstrates,&#148; &#147;design,&#148; &#147;estimates,&#148; &#147;expectation,&#148; &#147;expects,&#148; &#147;forecasts,&#148; &#147;future,&#148; &#147;goal,&#148; &#147;help,&#148; &#147;hopeful,&#148;
&#147;inform,&#148; &#147;informed,&#148; &#147;intends,&#148; &#147;may,&#148; &#147;might,&#148; &#147;on track,&#148; &#147;planned,&#148; &#147;planning,&#148; &#147;plans,&#148; &#147;positions,&#148; &#147;potential,&#148; &#147;powers,&#148;
&#147;predicts,&#148; &#147;predictive,&#148; &#147;projects,&#148; &#147;seeks,&#148; &#147;should,&#148; &#147;will,&#148; &#147;will achieve,&#148; &#147;will be,&#148; &#147;would&#148; or similar expressions and the negatives of those terms.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In particular, this prospectus supplement, and the documents we incorporate by reference in this prospectus supplement, contain
forward-looking statements relating to, among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The initiation of the commercial launch of Rezdiffra<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP>
(resmetirom) for the treatment of adults with noncirrhotic <FONT STYLE="white-space:nowrap">non-alcoholic</FONT> steatohepatitis (&#147;NASH&#148;) with moderate to advanced liver fibrosis in the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Anticipated or estimated future results, including the risks and uncertainties associated with our future
operating performance and financial position, and our projected resources and sufficiency of capital to fund our operating expenses; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our possible or assumed future results of operations and expenses, business strategies and plans (including
potential <FONT STYLE="white-space:nowrap">ex-U.S.</FONT> commercialization or partnering opportunities), capital needs and financing plans, including incurrence of indebtedness and compliance with debt covenants under the Loan and Security
Agreement with Hercules Capital, Inc., as agent and lender, market trends, market sizing, competitive position, industry environment and potential growth opportunities, among other things; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Post-approval requirements and commitments, including verification of a clinical benefit in confirmatory trials;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our ability to delay certain research activities and related clinical expenses as necessary;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our clinical trials, including the anticipated timing of disclosure, presentations of data from, or outcomes from
our trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Research and development activities, and the timing and results associated with the future development of
Rezdiffra / resmetirom, including projected market size, sector leadership, and patient treatment estimates for NASH and <FONT STYLE="white-space:nowrap">non-alcoholic</FONT> fatty liver disease (&#147;NAFLD&#148;) patients; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The timing and completion of projected future clinical milestone events, including enrollment, additional
studies, <FONT STYLE="white-space:nowrap">top-line</FONT> data and open label projections; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Rezdiffra&#146;s potential to be a cost-effective specialty therapy for NASH patients with significant liver
fibrosis (consistent with fibrosis stages 2 and 3); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Projections or objectives for obtaining full approval for resmetirom for NASH patients with significant fibrosis
(or <FONT STYLE="white-space:nowrap">non-cirrhotic</FONT> NASH patients) and NASH patients with compensated cirrhosis, including all statements concerning potential clinical benefit to support approval and/or potential approval;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Estimates of patients diagnosed with NASH; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our primary and key secondary study endpoints for resmetirom, and the potential for achieving such endpoints and
projections, including NASH resolution, safety, fibrosis treatment, cardiovascular effects and lipid treatment with resmetirom; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The relationship between NASH progression and adverse patient outcomes; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The estimated clinical burden of uncontrolled NASH; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Analyses for patients with NASH with significant fibrosis concerning potential progression to cirrhosis,
decompensated cirrhosis, liver transplant or death, and cardiovascular risks, comorbidities and outcomes; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Optimal dosing levels for resmetirom and projections regarding potential NASH or NAFLD and potential patient
benefits with resmetirom, including future NASH resolution, safety, fibrosis treatment, cardiovascular effects, lipid treatment and/or biomarker effects with resmetirom; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our ability to address the unmet needs of patients suffering from NASH with significant fibrosis;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The potential efficacy and safety of resmetirom for <FONT STYLE="white-space:nowrap">non-cirrhotic</FONT> NASH
patients and cirrhotic NASH patients; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The potential for resmetirom to become the
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class</FONT></FONT> treatment option for patients with NASH and significant fibrosis; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Strategies, objectives and commercial opportunities, including potential prospects or results;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Potential <FONT STYLE="white-space:nowrap">ex-U.S.</FONT> commercialization or partnering opportunities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The ability to develop clinical evidence demonstrating the utility of
<FONT STYLE="white-space:nowrap">non-invasive</FONT> tools and techniques to screen and diagnose NASH and/or NAFLD patients; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The predictive power of liver fat reduction with resmetirom, as measured by
<FONT STYLE="white-space:nowrap">non-invasive</FONT> tests, on NASH resolution and/or fibrosis reduction or improvement, and potential NASH or NAFLD patient risk profile benefits with resmetirom; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The predictive power of liver fat, liver volume changes or MAST scores for NASH and/or NAFLD patients;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The predictive power of NASH resolution and/or fibrosis reduction with resmetirom or improvement using <FONT
STYLE="white-space:nowrap">non-invasive</FONT> tests, including the use of ELF, FibroScan, MRE and/or <FONT STYLE="white-space:nowrap">MRI-PDFF;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The predictive power of <FONT STYLE="white-space:nowrap">non-invasive</FONT> tests generally, including for
purposes of diagnosing NASH, monitoring patient response to resmetirom, or recruiting and conducting a NASH clinical trial; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Market demand for and acceptance of our products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Research, development and commercialization of new products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The potential for resmetirom to be an effective treatment for other disease indications; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Obtaining and maintaining regulatory approvals, including, but not limited to, potential regulatory delays or
rejections; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Risks associated with meeting the objectives of our clinical studies, including, but not limited to our ability
to achieve enrollment objectives concerning patient numbers (including an adequate safety database), outcomes objectives and/or timing objectives for our studies, any delays or failures in enrollment, the occurrence of adverse safety events, and the
risks of successfully conducting trials that are substantially larger, and have patients with different disease states, than our past trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The potential impact of cyber attacks and other security incidents on our operations or business;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our continued reliance on third-party contract manufacturers for the manufacture of our products and product
candidates, including resmetirom; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Risks related to the effects of resmetirom&#146;s mechanism of action and our ability to accomplish our business
and business development objectives and realize the anticipated benefit of any such transactions; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Assumptions underlying any of the foregoing. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We caution you that the foregoing list may not include all of the forward-looking statements made in this prospectus supplement. Although
management presently believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove to be correct and you should be aware that actual results could differ
materially from those contained in the forward-looking statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Forward-looking statements are subject to a number of risks and
uncertainties including, but not limited to: our clinical and commercial development of resmetirom; the challenges with the commercial launch of a new product, particularly for a company that does not have commercial experience; enrollment and trial
outlook uncertainties, generally, based on blinded, locked or limited trial data; our potential inability to raise sufficient capital to fund our ongoing operations as currently planned or to obtain financings on terms similar to those we have
arranged in the past; our ability to meet post-approval commitments and requirements, including completion of enrollment of&#151;and ability to obtain positive data from&#151;any confirmatory studies required by the FDA; our ability to service our
indebtedness and otherwise comply with our debt covenants; outcomes or trends from competitive studies; future topline data timing or results; the risks of achieving potential benefits in studies that includes substantially more patients, and
patients with different disease states, than our prior studies; our ability to prevent and/or mitigate cybersecurity attacks, unauthorized exfiltration of data or other security incidents; limitations associated with early stage or <FONT
STYLE="white-space:nowrap">non-placebo</FONT> controlled study data; the timing and outcomes of clinical studies of resmetirom; and the uncertainties inherent in clinical testing; and uncertainties concerning analyses or assessments outside of a
controlled clinical trial. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Madrigal undertakes no obligation to update any forward-looking statements to reflect new information,
events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events. Please refer to Madrigal&#146;s submissions filed or furnished with the U.S. Securities and Exchange Commission for more detailed information
regarding these risks and uncertainties and other factors that may cause actual results to differ materially from those expressed or implied.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We specifically discuss these risks and uncertainties in greater detail in the section appearing in Part I, Item&nbsp;1A of our Annual Report
on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2023, filed with the SEC on February&nbsp;28, 2024. You should read these documents and the other documents that we file or have filed with the SEC, with the
understanding that our actual future results may be materially different from the results expressed or implied by these forward-looking statements. See &#147;Incorporation of Certain Information by Reference&#148; in this prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, we operate in an evolving environment. New risks and uncertainties emerge from time to time and it is not possible for our
management to predict all risks and uncertainties, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual future results to be materially different from those
expressed or implied by any forward-looking statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as required by applicable law, we assume no obligation to update any
forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. We qualify all of our
forward-looking statements by these cautionary statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc694036_3"></A>PROSPECTUS SUPPLEMENT SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>This summary highlights information contained elsewhere in this prospectus supplement and the accompanying prospectus and in the documents
we incorporate by reference. This summary is not complete and does not contain all of the information that you should consider before deciding to invest in our securities. For a more complete understanding of our Company and this offering, you
should read this entire prospectus supplement and the accompanying prospectus carefully, including information under the heading &#147;Risk Factors&#148; in this prospectus supplement and the information incorporated by reference herein and therein,
including information under the heading &#147;Risk Factors&#148; contained in Part I, Item 1A of our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2023, filed with the SEC on
February&nbsp;28, 2024 and information in our other filings with the SEC. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis (&#147;NASH&#148;), also known as
metabolic dysfunction-associated steatohepatitis (&#147;MASH&#148;), a liver disease with high unmet medical need. In March 2024, we announced that Rezdiffra<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP> (resmetirom) has been granted
accelerated approval by the U.S. Food and Drug Administration (&#147;FDA&#148;) in conjunction with diet and exercise for the treatment of adults with noncirrhotic NASH with moderate to advanced liver fibrosis (consistent with stages F2 to F3
fibrosis). Continued approval for this indication may be contingent upon verification and description of clinical benefit in ongoing confirmatory trials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect to initiate the commercial launch of Rezdiffra in the second quarter of 2024. In support of our commercialization efforts we have
employed a national sales force consisting of approximately 150 to 200 sales representatives. As used herein, &#147;Rezdiffra&#148; refers to resmetirom approved by the FDA for the treatment of adults with NASH with moderate to advanced liver
fibrosis, and &#147;remetirom&#148; refers to, where applicable, Rezdiffra as well as resmetirom for the treatment of indications beyond NASH with moderate to advanced liver fibrosis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Rezdiffra is a once-daily, oral <FONT STYLE="white-space:nowrap">THR-</FONT><FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT> agonist designed to
target key underlying causes of NASH. NASH is a more advanced form of nonalcoholic fatty liver disease (&#147;NAFLD&#148;). NASH is a leading cause of liver-related mortality and an increasing burden on healthcare systems globally. Additionally,
patients with NASH, especially those with more advanced metabolic risk factors (hypertension, concomitant type 2 diabetes), are at increased risk for adverse cardiovascular events and increased morbidity and mortality. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Once patients progress to NASH with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis), the risk of adverse liver
outcomes increases dramatically. NASH is rapidly becoming the leading cause of liver transplantation in the U.S. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NASH is also known as
MASH following a change in disease nomenclature introduced by hepatology medical societies in 2023. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recent Developments </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>FDA Accelerated Approval of Rezdiffra for the Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver Fibrosis </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accelerated approval of Rezdiffra was based on results from the Company&#146;s Phase 3 MAESTRO-NASH trial, which was recently published in
the New England Journal of Medicine. MAESTRO-NASH is an ongoing pivotal, multicenter, randomized, double-blind, placebo-controlled trial that enrolled 1,759 patients with biopsy-confirmed NASH. Following 52 weeks of treatment, both 100 mg and 80 mg
doses of Rezdiffra demonstrated statistically significant improvement compared to placebo on two primary endpoints: NASH resolution </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(including a reduction in the nonalcoholic fatty liver disease [NAFLD] activity score by &#8805;2 points) with no worsening of fibrosis, and an improvement in fibrosis by at least one stage with
no worsening of the NAFLD activity score. Fibrosis improvement and NASH resolution were consistent regardless of age, gender, type 2 diabetes status, or fibrosis stage. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Rezdiffra prescribing information does not include a liver biopsy requirement for diagnosis. The recommended dosage of Rezdiffra is based
on actual body weight. For patients weighing &lt;100 kg (220 lbs.), the recommended dosage is 80 mg orally once daily. For patients weighing &#8805;100 kg (220 lbs.), the recommended dosage is 100 mg orally once daily.<I> </I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">MAESTRO-NASH remains ongoing as an outcomes study designed to generate confirmatory data that, if positive, will help verify clinical benefit
and may support full approval. A second ongoing outcomes trial is evaluating progression to liver decompensation events in patients with well-compensated NASH cirrhosis treated with Rezdiffra versus placebo. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Rezdiffra should not be used in patients with decompensated cirrhosis. The most common adverse reactions reported in patients treated with
Rezdiffra included diarrhea, nausea, pruritis, abdominal pain, vomiting, constipation, and dizziness. Diarrhea and nausea typically began early in treatment initiation and were mild to moderate in severity. A separate, noninvasive Phase 3 trial, <FONT
STYLE="white-space:nowrap">MAESTRO-NAFLD-1,</FONT> evaluated the safety and tolerability of Rezdiffra and contributed to the safety database supporting regulatory benefit-risk assessment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Rezdiffra is expected to be available to patients in the U.S. in April and will be distributed through a limited specialty pharmacy network.
The Company is committed to helping appropriate patients who may benefit from Rezdiffra access the medication through the Madrigal Patient Support program. This program is designed to help patients navigate insurance and affordability challenges and
provide <FONT STYLE="white-space:nowrap">co-pay</FONT> support for eligible patients. Madrigal has also established a patient assistance program to help patients with no insurance access Rezdiffra. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>European Medicines Agency Validation of Madrigal&#146;s Marketing Authorization Application for Resmetirom for the Treatment of NASH/MASH with Liver
Fibrosis </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&nbsp;5, 2024, the Company announced that its Marketing Authorization Application for resmetirom for the treatment of
NASH with liver fibrosis has been validated and is now under evaluation with the European Medicines Agency&#146;s Committee for Medicinal Products for Human Use. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Phase 3 MAESTRO-NASH Trial Results </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">MAESTRO-NASH is an ongoing Phase 3 trial that enrolled 1,759 patients with biopsy-confirmed NASH. Patients were randomly assigned in a 1:1:1
ratio to receive once-daily Rezdiffra at a dose of 80 mg or 100 mg or placebo. The two primary endpoints at week 52 were NASH resolution with no worsening of fibrosis and an improvement in fibrosis by at least one stage with no worsening of the
NAFLD activity score. The key secondary endpoint was the percent change from baseline in LDL cholesterol at week 24. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Rezdiffra achieved
both primary endpoints and the key secondary endpoint of the MAESTRO-NASH trial. Additionally, Rezdiffra improved liver enzymes, fibrosis biomarkers and imaging tests as compared with placebo. The primary results of the trial were published in the
New England Journal of Medicine in February 2024. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Patients enrolled in the MAESTRO-NASH trial continue on therapy after the initial <FONT
STYLE="white-space:nowrap">52-week</FONT> treatment period for up to 54 months to accrue and measure hepatic clinical outcome events including progression to cirrhosis on biopsy and hepatic decompensation events, as well as <FONT
STYLE="white-space:nowrap">all-cause</FONT> mortality. The <FONT STYLE="white-space:nowrap">54-month</FONT> outcomes portion of the trial is designed to generate confirmatory data that, if positive, will help verify Rezdiffra&#146;s clinical benefit
and may support full approval. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We were incorporated in Delaware in September 2011. Our principal executive offices are located at 200 Barr Harbor Drive, Suite 200, West
Conshohocken, Pennsylvania 19428. Our telephone number is (267) <FONT STYLE="white-space:nowrap">824-2827.</FONT> Our website address is <I>www.madrigalpharma.com</I>. The contents of our website are not incorporated into, and do not form a part of,
this prospectus supplement or the registration statement of which it forms a part. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The Offering </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>The following summary contains basic information about our securities and the offering and is not intended to be complete. It does not
contain all of the information that may be important to you. For a more complete understanding of our securities, you should read the sections entitled &#147;Description of <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants&#148; in this
prospectus supplement and &#147;Description of Securities to Be Offered&#148; in the accompanying prospectus. </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Common stock offered by us</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&#8195;&#8195;&#8195;shares (or &#8195;&#8195;&#8195;shares if the underwriters exercise in full their option to purchase &#8195;&#8195;&#8195;additional shares).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B><FONT STYLE="white-space:nowrap">Pre-funded</FONT> warrants offered by us</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">We are also offering <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants to purchase &#8195;&#8195;&#8195;shares of common stock. The purchase price of each <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant will
equal the price per share at which the shares of common stock are being sold to the public in this offering, minus $ &#8195;&#8195;, which is the exercise price of each <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant. Each <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrant will be exercisable from the date of issuance until fully exercised, subject to an ownership limitation. This prospectus supplement also relates to the offering of the shares of common stock
issuable upon exercise of such <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Option to purchase additional shares</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">We have granted the underwriters an option to purchase up to &#8195;&#8195;&#8195;additional shares of our common stock from us at the public offering price, less the underwriting discounts and commissions payable by us. This option
is exercisable, in whole or in part, for a period of 30 days following the date of this prospectus supplement.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Common stock to be outstanding after this
offering<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&#8195;&#8195;&#8195;shares (or &#8195;&#8195;&#8195;shares if the underwriters exercise in full their option to purchase additional shares), which excludes any shares of common stock issuable upon exercise of the <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Use of Proceeds</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">We estimate that the net proceeds from this offering to us will be approximately $ &#8195;&#8195;&#8195;million based on the sale of &#8195;&#8195;&#8195;shares of our common stock and
<FONT STYLE="white-space:nowrap">&#8195;&#8195;&#8195;pre-funded</FONT> warrants offered hereby (or approximately $ &#8195;&#8195;&#8195;million if the underwriters exercise their option to purchase an additional &#8195;&#8195;&#8195;shares from us
in full), after deducting estimated underwriting discounts and commissions and estimated offering expenses.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">We intend to use the net proceeds from this offering for our commercial activities in connection with the launch of Rezdiffra in the U.S. and general corporate purposes, including, without limitation, research and development
expenditures, ongoing clinical trial expenditures, manufacture and supply of drug substance and drug products, potential acquisitions or licensing of new technologies, potential
<FONT STYLE="white-space:nowrap">ex-U.S.</FONT></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">commercialization or partnering opportunities, capital expenditures and working capital. See &#147;Use of Proceeds&#148; beginning on page <FONT STYLE="white-space:nowrap">S-16</FONT> of this prospectus supplement.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Nasdaq Global Select Market Symbol</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Our common stock is listed on The Nasdaq Global Select Market under the symbol &#147;MDGL.&#148; We do not intend to list the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants on The Nasdaq Global Select Market or any
other national securities exchange or nationally recognized trading system. Without an active market, the liquidity of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants will be limited.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Risk Factors</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Your investment in our securities involves substantial risks. You should read carefully the &#147;Risk Factors&#148; included and incorporated by reference in this prospectus supplement, including the risk factors incorporated by
reference from our filings with the SEC.</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The number of shares of our common stock to be outstanding after the offering is based on 19,875,427 shares of
our common stock outstanding as of December&nbsp;31, 2023 and excludes the following: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1,969,797 shares of our common stock issuable upon conversion of our Series A Convertible Preferred Stock, and
400,000 shares of our common stock issuable upon conversion of our Series B Convertible Preferred Stock, each as outstanding as of December&nbsp;31, 2023; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">2,355,779 shares of our common stock issuable upon the exercise of options outstanding as of December&nbsp;31,
2023, having a weighted average exercise price of $79.94 per share (less 1,500 shares of our common stock issued upon the exercise of options subsequent to December&nbsp;31, 2023 through March&nbsp;8, 2024, at a weighted average exercise price of
$70.52 per share and less 9,526 shares of our common stock underlying options that were cancelled or expired subsequent to December&nbsp;31, 2023 through March&nbsp;8, 2024, at a weighted average exercise price of $85.35 per share);
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">133,891 shares of common stock issuable upon the exercise of options granted subsequent to December&nbsp;31, 2023
under our 2015 Stock Plan and 2023 Inducement Plan, having a weighted average exercise price of $151.78 per share as of March&nbsp;8, 2024; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">44,563 shares of our common stock issued upon the vesting of restricted stock units and performance stock units
subsequent to December&nbsp;31, 2023 through March&nbsp;8, 2024; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">526,117 shares of our common stock issuable upon the vesting of restricted stock units and performance stock
units outstanding as of December&nbsp;31, 2023 (less 44,563 shares of our common stock issued upon the vesting of restricted stock units and performance stock units subsequent to December&nbsp;31, 2023 through March&nbsp;8, 2024, less 3,407 shares
of our common stock issuable upon the vesting of restricted stock units that were forfeited subsequent to December&nbsp;31, 2023 through March&nbsp;8, 2024, and plus an aggregate of 253,721 shares of our common stock issuable upon the vesting of
restricted stock units and performance stock units granted subsequent to December&nbsp;31, 2023 under our 2015 Stock Plan and 2023 Inducement Plan as of March&nbsp;8, 2024); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an aggregate of 711,054 shares of our common stock reserved for future issuance as of December&nbsp;31, 2023
under our 2015 Stock Plan (less 79,850 shares of our common stock issuable upon the exercise of options granted subsequent to December&nbsp;31, 2023 through March&nbsp;8, 2024 under our 2015 Stock Plan, less 154,232 shares of our common stock
issuable upon the vesting of restricted stock units and performance stock units granted subsequent to December&nbsp;31, 2023 under our 2015 Stock Plan, plus 9,526 shares of our common
</P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
stock underlying options that were cancelled or expired subsequent to December&nbsp;31, 2023 through March&nbsp;8, 2024 and plus 3,208 shares of our common stock issuable upon the vesting of
restricted stock units that were forfeited subsequent to December&nbsp;31, 2023 through March&nbsp;8, 2024); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an aggregate of 193,392 shares of our common stock reserved for future issuance under our 2023 Inducement Plan as
of December&nbsp;31, 2023 (less 54,041 shares of our common stock issuable upon the exercise of options granted subsequent to December&nbsp;31, 2023 through March&nbsp;8, 2024 under our 2023 Inducement Plan, less 99,489 shares of our common stock
issuable upon the vesting of restricted stock units and performance stock units granted subsequent to December&nbsp;31, 2023 under our 2015 Stock Plan, plus 199 shares of our common stock issuable upon the vesting of restricted stock units that were
forfeited subsequent to December&nbsp;31, 2023 through March&nbsp;8, 2024); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">$174.8&nbsp;million of our common stock available for future issuance pursuant to the <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">at-the-market</FONT></FONT> sales agreement between us and Cowen and Company, LLC, dated June&nbsp;1, 2021, as amended (the &#147;Sales Agreement&#148;) under the prospectus supplement
dated May&nbsp;9, 2023 (the &#147;May 2023 Prospectus Supplement&#148;), as of December&nbsp;31, 2023; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">19,454 shares of our common stock issuable upon the exercise of warrants issued to Hercules Capital, Inc.
(&#147;Hercules&#148;) under warrant agreements between us and Hercules (the &#147;Warrant Agreements&#148;), as of December&nbsp;31, 2023; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">2,048,098 shares of our common stock issuable upon the exercise of
<FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants at an exercise price of a $0.0001 per share, as of December&nbsp;31, 2023; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8195;&#8195;&#8195;shares of common stock issuable upon the exercise of the
<FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants being offered by us in this offering. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as otherwise
noted, all information in this prospectus supplement assumes no exercise by the underwriters of their option to purchase additional shares of our common stock. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc694036_4"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Before making an investment decision, you should carefully consider the risks described below and discussed in the section titled
&#147;Risk Factors&#148; in our most recent Annual Report on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> as well as the risks, uncertainties and additional information set forth in our SEC reports on Forms
<FONT STYLE="white-space:nowrap">10-K,</FONT> <FONT STYLE="white-space:nowrap">10-Q</FONT> and <FONT STYLE="white-space:nowrap">8-K,</FONT> including after the date of this prospectus supplement, and in other documents incorporated by reference in
this prospectus supplement and the accompanying prospectus. We expect to update these Risk Factors from time to time in the periodic and current reports that we file with the SEC after the date of this prospectus supplement. These updated Risk
Factors will be incorporated by reference in this prospectus supplement. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Our business, financial condition or results of
operations could be materially adversely affected by any of these risks. The trading price of our common stock could decline due to any of these risks, and you may lose all or part of your investment. The risks and uncertainties we have described
are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also affect our business, financial condition results of operations and prospects. Certain statements below are
forward-looking statements. See the information included under the heading &#147;Cautionary Note Regarding Forward-Looking Statements.&#148; </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks
Related to the Company </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>In order to execute our business plan and achieve profitability, we need to effectively commercialize
Rezdiffra, which received FDA approval in March 2024 for the treatment of adults with NASH with moderate to advanced liver fibrosis. We may not be able to meet expectations with respect to sales of Rezdiffra or attain profitability and positive
cash-flow from operations. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Rezdiffra is our only drug that has been approved for sale and it has been approved only for the
treatment of adults with noncirrhotic NASH with moderate to advanced liver fibrosis in the United States. We are focusing a significant portion of our activities and resources on Rezdiffra, and we believe our prospects are highly dependent on, and a
significant portion of the value of our company relates to, our ability to successfully commercialize Rezdiffra for the treatment of adults with NASH with moderate to advanced liver fibrosis in the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Successful commercialization of Rezdiffra is subject to many risks. We have never, as an organization, launched or commercialized any product,
and there is no guarantee that we will be able to successfully commercialize Rezdiffra for its approved indication. There are numerous examples of failures to meet high expectations of market potential, including by pharmaceutical companies with
more experience and resources than us. We are in the process of building our commercial organization and hiring our U.S. sales force and will need to refine and further develop our commercial organization in order to successfully commercialize
Rezdiffra. We expect that the initial commercial success of Rezdiffra for the treatment of NASH will depend on many factors, including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the efficacy, cost, approved use, and side-effect profile of Rezdiffra regimens relative to competitive treatment
regimens for the treatment of NASH; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Rezdiffra may compete with the <FONT STYLE="white-space:nowrap">off-label</FONT> use of currently marketed
products and other therapies in development that may in the future obtain approval for NASH; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effectiveness of our commercial strategy for the marketing of Rezdiffra, including our pricing strategy and
the effectiveness of our efforts to obtain adequate third-party reimbursements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developing, maintaining and successfully monitoring commercial manufacturing arrangements for Rezdiffra with
third-party manufacturers to ensure they meet our standards and those of regulatory authorities, including the FDA, which extensively regulate and monitor pharmaceutical manufacturing facilities; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to&nbsp;negotiate and enter into any additional commercial, supply and distribution contracts to
support commercialization efforts, and&nbsp;to hire and manage additional qualified personnel; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to meet the demand for commercial supplies of Rezdiffra at acceptable costs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the acceptance of Rezdiffra by physicians, patients and third-party payors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to remain compliant with laws and regulations that apply to us and our commercial activities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the actual <FONT STYLE="white-space:nowrap">market-size,</FONT> ability to identify targeted patients and the
demographics of patients eligible for Rezdiffra, which may be different than what we currently expect; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the occurrence of any side effects, adverse reactions or misuse, or any unfavorable publicity in these areas;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to obtain, maintain or enforce our patents and other intellectual property rights; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effect of recent or potential health care legislation in the United States. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While we believe that Rezdiffra for the treatment of NASH should have a commercially competitive profile, we cannot accurately predict the
amount of time needed to attain a commercially successful profile or the&nbsp;amount of revenue that would be generated from the sale of Rezdiffra. If we do not effectively commercialize Rezdiffra, we will not be able to execute our business plan
and may not be able to achieve profitability. If our revenues, market share and/or other indicators of market acceptance of Rezdiffra do not meet the expectations of investors or public market analysts, the market price of our common stock would
likely decline. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Rezdiffra has received accelerated approval from the FDA, and therefore faces future post-approval development and regulatory
requirements, which present additional challenges&nbsp;for us to successfully navigate. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA granted accelerated approval of
Rezdiffra for the treatment of adults with noncirrhotic NASH with moderate to advanced liver fibrosis in the United States in March 2024. Under the accelerated approval pathway, continued approval may be contingent upon verification of a clinical
benefit in confirmatory trials. These post-approval requirements and commitments may not be feasible and/or could impose significant burdens and costs on us; could negatively impact our development, manufacturing and supply of our products; and
could negatively impact our financial results. Drugs granted accelerated approval must meet the same statutory standards for safety and effectiveness as those granted traditional approval. Failure to meet post-approval commitments and requirements,
including completion of enrollment of&#151;and in particular, any failure to obtain positive data from&#151;any confirmatory studies required by the FDA, could result in negative regulatory action from the FDA and/or withdrawal of such accelerated
approval. The recently enacted Food and Drug Omnibus Reform Act has expanded FDA&#146;s expedited withdrawal procedures for drugs approved through the accelerated approval pathway if a sponsor fails to conduct any required post-approval study with
due diligence. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise informed by the FDA, an applicant must submit to the FDA for consideration during the preapproval review
period copies of all promotional materials, including promotional labeling as well as advertisements, intended for dissemination or publication within 120 days following marketing approval. After 120 days following marketing approval, unless
otherwise informed by the FDA, the applicant must submit promotional materials at least 30 days prior to the intended time of initial dissemination of the labeling or initial publication of the advertisement. If we or the manufacturing facilities
for our products fail to comply with applicable regulatory requirements, the FDA may, among other actions: issue warning letters or untitled letters; seek an injunction or impose civil or criminal penalties or monetary fines; suspend or withdraw or
alter the conditions of our marketing approval; suspend any ongoing clinical trials; refuse to approve pending applications or supplements to applications submitted by us; suspend or impose restrictions on operations, including costly new
manufacturing requirements; and seize or detain products, refuse to permit the import or export of products or require us to initiate a product recall. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to This Offering </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Investors in this offering will pay a much higher price than the book value of our common stock. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you purchase securities in this offering, you will incur an immediate and substantial dilution in the adjusted net tangible book value of
the common stock that you purchase or that is issuable upon exercise of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants of $&#8195;&#8195;&#8195; per share, representing the difference between each of the public offering price of $
&#8195;&#8195;&#8195;per share and the public offering price of $ &#8195;&#8195;&#8195;per <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant and our as adjusted net tangible book value per share as of December&nbsp;31, 2023 after giving
effect to this offering and assuming no exercise of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants issued in this offering, and after deducting underwriting discounts and commissions for shares sold in this offering and estimated
offering expenses payable by us. See &#147;Dilution.&#148; To the extent outstanding options or warrants we have issued are ultimately exercised, you will incur additional dilution. Furthermore, if the underwriter exercises its option to purchase
additional shares, you will also incur additional dilution. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our management will have broad discretion over the use of the net proceeds from this
offering; you may not agree with how we use the proceeds and the proceeds may not be invested successfully. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our management will
have broad discretion as to the use of the net proceeds from this offering by us and could use them for purposes other than those contemplated at the time of this offering. Accordingly, you may be relying on the judgment of our management with
regard to the use of these net proceeds, and you will not have the opportunity, as part of your investment decision, to assess whether the proceeds are being used appropriately. It is possible that the proceeds will be invested in a way that does
not yield a favorable, or any, return for us. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Sales of additional shares of our common stock, including by us or our directors, officers and
significant stockholders, could cause the price of our common stock to decline. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sales of substantial amounts of our common stock
in the public market, or the availability of such shares for sale, by us or others, including the issuance of common stock upon exercise of outstanding options, warrants or upon the conversion of our Series A Convertible Preferred Stock or Series B
Convertible Preferred Stock, could adversely affect the price of our common stock. In connection with this offering, we, our directors and officers and have entered into <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements with the
underwriters under which we, our directors and officers have agreed, subject to specific exceptions described in the section titled &#147;Underwriting&#148;, not to sell, directly or indirectly, any shares of common stock without the permission of
Goldman Sachs&nbsp;&amp; Co. LLC for a period of 60 days following the date of this prospectus supplement. Upon expiration or earlier release of the <FONT STYLE="white-space:nowrap">lock-up,</FONT> we, our directors or officers may sell shares into
the market, which could adversely affect the market price of shares of our common stock. Sales of a substantial number of such shares upon expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements, the perception that such sales
may occur, or early release of these agreements, could cause our market price to fall or make it more difficult for you to sell your common stock at a time and price that you deem appropriate. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>There is no public market for the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants being offered in this offering. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is no established public trading market for the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants being offered in this
offering, and we do not expect a market to develop. In addition, we do not intend to apply to list the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants on any securities exchange or nationally recognized trading system, including the
Nasdaq Global Select Market. Without an active market, the liquidity of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants will be limited. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Holders of <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants purchased in this offering will have no rights as common stockholders until such
holders exercise their <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants and acquire our common stock. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Until holders of <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants acquire shares of our common stock upon exercise of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants, holders of <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants will
have no rights with respect to the shares of our common stock underlying such <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants. Upon exercise of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants, the holders will be entitled
to exercise the rights of a common stockholder only as to matters for which the record date occurs after the exercise date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Significant holders or beneficial holders of shares of our common stock may not be permitted to
exercise the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants that they hold. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A holder of the <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants will not be entitled to exercise any portion of any <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant that, upon giving effect to such exercise, would cause the aggregate number of
shares of our common stock beneficially owned by such holder (together with its affiliates) to exceed 9.99% of the number of shares of our common stock immediately after giving effect to the exercise, as such percentage ownership is determined in
accordance with the terms of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants. However, any holder may increase or decrease such percentage (not in excess of 19.99%) upon at least 61 days&#146; prior notice from the holder to us. As a
result, you may not be able to exercise your <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants for shares of our common stock at a time when it would be financially beneficial for you to do so. In such a circumstance, you could seek to
sell your <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants to realize value, but you may be unable to do so in the absence of an established trading market and due to applicable transfer restrictions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc694036_5"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We estimate that the net proceeds from the sale of securities that we are selling in this offering will be approximately
$&#8195;&#8195;&#8195; million based on the sale of &#8195;&#8195;&#8195;shares of our common stock and <FONT STYLE="white-space:nowrap">&#8195;&#8195;&#8195;pre-funded</FONT> warrants offered hereby, or approximately $ &#8195;&#8195;&#8195;million
if the underwriters exercise in full their option to purchase an additional &#8195;&#8195;&#8195;shares of common stock from us, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. We will
receive nominal proceeds, if any, from any exercise of <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to use the
net proceeds from this offering for our commercial activities in connection with the launch of Rezdiffra in the U.S. and general corporate purposes, including, without limitation, research and development expenditures, ongoing clinical trial
expenditures, manufacture and supply of drug substance and drug products, potential acquisitions or licensing of new technologies, potential <FONT STYLE="white-space:nowrap">ex-U.S.</FONT> commercialization or partnering opportunities, capital
expenditures and working capital. We may temporarily invest the net proceeds in short-term, interest-bearing instruments, including obligations of U.S. government agencies, U.S. Treasury debt securities, corporate debt securities and money market
funds. We have not determined the amount of net proceeds to be used specifically for such purposes. As a result, management will retain broad discretion over the allocation of net proceeds. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc694036_6"></A>DILUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you purchase our securities in this offering, your interest will be diluted to the extent of the difference between the public offering
price per share of common stock or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant and the net tangible book value per share of our common stock after this offering. We calculate net tangible book value per share by subtracting our total
liabilities from our total tangible assets and dividing the difference by the number of outstanding shares of our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our net
tangible book value at December&nbsp;31, 2023 was approximately $403.6&nbsp;million, or $20.31 per share, based on 19,875,427 shares of our common stock then outstanding. Historical net tangible book value per share is equal to our total tangible
assets, less total liabilities, divided by the number of outstanding shares of our common stock. Dilution in net tangible book value per share represents the difference between the amount per share paid by purchasers of shares of common stock or <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants in this offering and the net tangible book value per share of our common stock immediately after this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After giving effect to the sale by us of (i) &#8195;&#8195;&#8195; shares of common stock in this offering at a public offering price of $
&#8195;&#8195;&#8195;per share of common stock, and <FONT STYLE="white-space:nowrap">(ii)&nbsp;pre-funded</FONT> warrants to purchase &#8195;&#8195;&#8195;shares of common stock in this offering at the offering price of $ &#8195;&#8195;&#8195;per <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrant (which equals the public offering price per share of the common stock less the $ &#8195;&#8195;&#8195;per share exercise price of each such <FONT STYLE="white-space:nowrap">pre-funded</FONT>
warrant) (and excluding shares of common stock issued and any proceeds received upon exercise of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants or any resulting accounting associated with the
<FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants), less the underwriting discounts and commissions and estimated offering expenses payable by us, our <FONT STYLE="white-space:nowrap">as-adjusted</FONT> net tangible book value at
December&nbsp;31, 2023 would have been approximately $ &#8195;&#8195;&#8195;million, or approximately $ &#8195;&#8195;&#8195;per share of common stock. This represents an immediate increase in net tangible book value of $ &#8195;&#8195;&#8195;per
share to existing stockholders and an immediate dilution in net tangible book value of $ &#8195;&#8195;&#8195;per share to investors in this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table illustrates this <FONT STYLE="white-space:nowrap">per-share</FONT> dilution: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public offering price per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Historical net tangible book value per share as of December&nbsp;31, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20.31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase in net tangible book value per share attributable to new investors purchasing shares in
this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">As adjusted net tangible book value per share immediately after this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dilution per share to new investors purchasing shares in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Assuming the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants were immediately and fully exercised,
this would result in an as adjusted net tangible book value after giving effect to this offering and warrant exercise of $&#8195;&#8195;&#8195; million, or $ &#8195;&#8195;&#8195;per share of common stock, which represents a dilution per share to
new investors of $&#8195;&#8195;&#8195;, and an increase in net tangible book value per share to existing stockholders of $&#8195;&#8195;&#8195;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the amounts in the table above assume no exercise by the underwriters of their option to purchase additional shares of our common
stock. If the underwriters exercise their option in full to purchase additional shares of our common stock in this offering at the public offering price of $&#8195;&#8195;&#8195; per share, and assuming the
<FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants were not immediately and fully exercised, the <FONT STYLE="white-space:nowrap">as-adjusted</FONT> net tangible book value per share after the offering would be $ &#8195;&#8195;&#8195;per
share of common stock, the increase in net tangible book value per share to existing stockholders would be $ &#8195;&#8195;&#8195;per share and the dilution in net tangible book value per share to investors in this offering would be $
&#8195;&#8195;&#8195;per share. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The number of shares of our common stock to be outstanding after the offering is based on 19,875,427 shares
of our common stock outstanding as of December&nbsp;31, 2023 and excludes the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1,969,797 shares of our common stock issuable upon conversion of our Series A Convertible Preferred Stock, and
400,000 shares of our common stock issuable upon conversion of our Series B Convertible Preferred Stock, each as outstanding as of December&nbsp;31, 2023; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">2,355,779 shares of our common stock issuable upon the exercise of options outstanding as of December&nbsp;31,
2023, having a weighted average exercise price of $79.94 per share (less 1,500 shares of our common stock issued upon the exercise of options subsequent to December&nbsp;31, 2023 through March&nbsp;8, 2024, at a weighted average exercise price of
$70.52 per share and less 9,526 shares of our common stock underlying options that were cancelled or expired subsequent to December&nbsp;31, 2023 through March&nbsp;8, 2024, at a weighted average exercise price of $85.35 per share);
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">133,891 shares of common stock issuable upon the exercise of options granted subsequent to December&nbsp;31, 2023
under our 2015 Stock Plan and 2023 Inducement Plan, having a weighted average exercise price of $151.78 per share as of March&nbsp;8, 2024; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">44,563 shares of our common stock issued upon the vesting of restricted stock units and performance stock units
subsequent to December&nbsp;31, 2023 through March&nbsp;8, 2024; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">526,117 shares of our common stock issuable upon the vesting of restricted stock units and performance stock
units outstanding as of December&nbsp;31, 2023 (less 44,563 shares of our common stock issued upon the vesting of restricted stock units and performance stock units subsequent to December&nbsp;3, 2023 through March&nbsp;8, 2024, less 3,407 shares of
our common stock issuable upon the vesting of restricted stock units that were forfeited subsequent to December&nbsp;31, 2023 through March&nbsp;8, 2024, and plus an aggregate of 253,721 shares of our common stock issuable upon the vesting of
restricted stock units and performance stock units granted subsequent to December&nbsp;31, 2023 under our 2015 Stock Plan and 2023 Inducement Plan as of March&nbsp;8, 2024); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an aggregate of 711,054 shares of our common stock reserved for future issuance as of December&nbsp;31, 2023
under our 2015 Stock Plan (less 79,850 shares of our common stock issuable upon the exercise of options granted subsequent to December&nbsp;31, 2023 through March&nbsp;8, 2024 under our 2015 Stock Plan, less 154,232 shares of our common stock
issuable upon the vesting of restricted stock units and performance stock units granted subsequent to December&nbsp;31, 2023 under our 2015 Stock Plan, plus 9,526 shares of our common stock underlying options that were cancelled or expired
subsequent to December&nbsp;31, 2023 through March&nbsp;8, 2024 and plus 3,208 shares of our common stock issuable upon the vesting of restricted stock units that were forfeited subsequent to December&nbsp;31, 2023 through March&nbsp;8, 2024);
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an aggregate of 193,392 shares of our common stock reserved for future issuance under our 2023 Inducement Plan as
of December&nbsp;31, 2023 (less 54,041 shares of our common stock issuable upon the exercise of options granted subsequent to December&nbsp;31, 2023 through March&nbsp;8, 2024 under our 2023 Inducement Plan, less 99,489 shares of our common stock
issuable upon the vesting of restricted stock units and performance stock units granted subsequent to December&nbsp;31, 2023 under our 2015 Stock Plan, plus 199 shares of our common stock issuable upon the vesting of restricted stock units that were
forfeited subsequent to December&nbsp;31, 2023 through March&nbsp;8, 2024); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">$174.8&nbsp;million of our common stock available for future issuance pursuant to the Sales Agreement under the
May 2023 Prospectus Supplement as of December&nbsp;31, 2023; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">19,454 shares of our common stock issuable upon the exercise of warrants issued to Hercules under the Warrant
Agreements, as of December&nbsp;31, 2023; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">2,048,098 shares of our common stock issuable upon the exercise of
<FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants at an exercise price of a $0.0001 per share, as of December&nbsp;31, 2023; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8195;&#8195;&#8195;shares of common stock issuable upon the exercise of the
<FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants being offered by us in this offering. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent options or warrants are exercised or our Series A Convertible Preferred Stock
or Series B Convertible Preferred Stock is converted into common stock, or we issue additional shares of common stock or other securities convertible into or exercisable for common stock in the future, there may be further dilution to investors
participating in this offering. In addition, we may choose to raise additional capital because of market conditions or strategic considerations, even if we believe that we have sufficient funds for our current or future operating plans. If we raise
additional capital through the sale of equity or convertible debt securities, the issuance of these securities could result in further dilution to our stockholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc694036_7"></A>DESCRIPTION OF
<FONT STYLE="white-space:nowrap">PRE-FUNDED</FONT> WARRANTS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a brief summary of certain terms and conditions of the <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants being offered by this prospectus supplement. The following description is subject in all respects to the provisions contained in the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Form.</I> The <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants will be issued as individual warrant agreements to the
investors. The form of <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant will be filed as an exhibit to our Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> that we expect to file with the SEC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Exercisability.</I> The <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants are exercisable at any time after their original
issuance. The <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants will be exercisable, at the option of each holder, in whole or in part by delivering to us a duly executed exercise notice and by payment in full in immediately available
funds for the number of shares of common stock purchased upon such exercise. As an alternative to payment in immediately available funds, the holder may, in its sole discretion, elect to exercise the
<FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant through a cashless exercise, in which case the holder would receive upon such exercise the net number of shares of common stock determined according to the formula set forth in the <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrant. No fractional shares of common stock will be issued in connection with the exercise of a <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant. In lieu of fractional shares, we will pay the
holder an amount in cash equal to the fractional amount multiplied by the fair market value of any such fractional shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Exercise
Limitations.</I> Under the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants, we may not effect the exercise of any <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant, and a holder will not be entitled to exercise any portion of
any <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant, which, upon giving effect to such exercise, would cause the aggregate number of shares of our common stock beneficially owned by the holder (together with its affiliates and certain
attribution parties) to exceed 9.99% of the number of shares of our common stock outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants. However, any holder may increase or decrease such percentage (not in excess of 19.99%) upon at least 61 days&#146; prior notice from the holder to us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Exercise Price</I>. The exercise price per whole share of our common stock purchasable upon the exercise of the <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants is $&#8195;&#8195;&#8195; per share of common stock. The exercise price of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants is subject to appropriate adjustment in the event of
certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting our common stock and also upon any distributions of assets, including cash, stock or other property to our stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Transferability</I>. Subject to applicable laws, the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants may be offered for sale,
sold, transferred or assigned without our consent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Exchange Listing</I>. We do not plan on applying to list the <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants on The Nasdaq Global Select Market, any other national securities exchange or any other nationally recognized trading system. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Fundamental Transactions</I>. In the event of a fundamental transaction, as described in the
<FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants and generally including any reorganization, recapitalization or reclassification of our common stock, the sale, transfer or other disposition of all or substantially all of our properties
or assets, our consolidation or merger with or into another person, the acquisition of more than 50% of our outstanding common stock, or any person or group becoming the beneficial owner of 50% of the voting power represented by our outstanding
common stock, the holders of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants will be entitled to receive upon exercise of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants the kind and amount of securities, cash or
other property that the holders would have received had they exercised the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants immediately prior to such fundamental transaction without regard to any limitations on exercised contained in the <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>No Rights as a Stockholder</I>. Except by virtue of such holder&#146;s
ownership of shares of our common stock, the holder of a <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant does not have the rights or privileges of a holder of our common stock, including any voting rights, until the holder exercises the <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrant. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc694036_8"></A>MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES TO <FONT
STYLE="white-space:nowrap">NON-U.S.</FONT> HOLDERS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a general discussion of the material U.S. federal income tax
consequences applicable to <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders (as defined herein) with respect to the purchase, ownership and disposition of our common stock issued or acquired pursuant to this offering. All prospective <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holders of our common stock should consult their tax advisors with respect to the U.S. federal, state, local and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> tax consequences of the purchase, ownership
and disposition of our common stock. In general, a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder means a beneficial owner of our common stock (other than a partnership or an entity or arrangement treated as a partnership for U.S. federal
income tax purposes) that is not, for U.S. federal income tax purposes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an individual who is a citizen or resident of the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a corporation, or an entity treated as a corporation, created or organized in the United States or under the laws
of the United States or of any state thereof or the District of Columbia; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an estate, the income of which is subject to U.S. federal income tax regardless of its source; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a trust if (1)&nbsp;a U.S. court can exercise primary supervision over the trust&#146;s administration and one or
more U.S. persons have the authority to control all of the trust&#146;s substantial decisions or (2)&nbsp;the trust has a valid election in effect under applicable U.S. Treasury Regulations to be treated as a U.S. person. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This discussion is based on current provisions of the U.S. Internal Revenue Code of 1986, as amended, or the Code, existing U.S. Treasury
Regulations promulgated thereunder, published administrative pronouncements and rulings of the U.S. Internal Revenue Service, or the IRS, and judicial decisions, all as in effect as of the date of this prospectus supplement. These authorities are
subject to change and to differing interpretation, possibly with retroactive effect. Any change or differing interpretation could alter the tax consequences to <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders described in this prospectus
supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We assume in this discussion that a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder holds our common stock as a
capital asset within the meaning of Section&nbsp;1221 of the Code (generally, property held for investment). This discussion does not address all aspects of U.S. federal income taxation that may be relevant to a particular <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder in light of that <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s individual circumstances, nor does it address any alternative minimum tax, Medicare contribution tax or investment
income, estate or gift tax consequences, or any aspects of U.S. state, local or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> taxes. This discussion also does not consider any specific facts or circumstances that may apply to a <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder and does not address the special tax rules applicable to particular <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders, such as holders that own, or are deemed to own, more than 5% of our
capital stock (except to the extent specifically set forth below), corporations that accumulate earnings to avoid U.S. federal income tax, <FONT STYLE="white-space:nowrap">tax-exempt</FONT> organizations, banks, financial institutions, insurance
companies, brokers, dealers or traders in securities, commodities or currencies, <FONT STYLE="white-space:nowrap">tax-qualified</FONT> retirement plans, holders who hold or receive our common stock pursuant to the exercise of employee stock options
or otherwise as compensation, holders holding our common stock as part of a hedge, straddle or other risk reduction strategy, conversion transaction or other integrated investment, &#147;qualified foreign pension funds&#148; as defined in
Section&nbsp;897(1)(2) of the Code, persons subject to special tax accounting under Section&nbsp;451(b) of the Code, holders deemed to sell our common stock under the constructive sale provisions of the Code, controlled foreign corporations, passive
foreign investment companies and certain former U.S. citizens or long-term residents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, this discussion does not address the
tax treatment of partnerships (or entities or arrangements that are treated as partnerships for U.S. federal income tax purposes) or persons that hold our common stock through partnerships. If a partnership, including any entity or arrangement
treated as a partnership for U.S. federal income tax purposes, holds our common stock, the U.S. federal income tax treatment of a partner in such partnership will generally depend upon the status of the partner and the activities of the partnership.
Such partners and partnerships should consult their tax advisors regarding the tax consequences of the purchase, ownership and disposition of our common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There can be no assurance that a court or the IRS will not challenge one or more of the tax
consequences described in this prospectus supplement, and we have not obtained, nor do we intend to obtain, a ruling or opinion of counsel with respect to the U.S. federal income tax consequences to a <FONT STYLE="white-space:nowrap">non-U.S.</FONT>
holder of the purchase, ownership or disposition of our common stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Distributions on Our Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Distributions, if any, on our common stock generally will constitute dividends for U.S. federal income tax purposes to the extent paid from our
current or accumulated earnings and profits, as determined under U.S. federal income tax principles. If a distribution exceeds our current and accumulated earnings and profits, the excess will be treated as a
<FONT STYLE="white-space:nowrap">tax-free</FONT> return of the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s investment, up to such <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s adjusted tax basis in the common
stock. Any remaining excess will be treated as capital gain from the sale or exchange of such common stock, subject to the tax treatment described below in &#147;Gain on Sale, Exchange or Other Disposition of Our Common Stock.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as otherwise described below, dividends paid to a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder will generally be subject to
withholding of U.S. federal income tax at a 30% rate or such lower rate as may be specified by an applicable income tax treaty. A <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder who claims the benefit of an applicable income tax treaty
generally will be required to satisfy certain certification and other requirements. Such <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders must generally provide us and/or our paying agent, as applicable, with a properly executed IRS Form <FONT
STYLE="white-space:nowrap">W-8BEN</FONT> or IRS Form <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> (or applicable successor form) claiming an exemption from or reduction in withholding under an applicable
income tax treaty. Such certificate must be provided before the payment of dividends and must be updated periodically. If tax is withheld in an amount in excess of the amount applicable under an income tax treaty, a refund of the excess amount may
generally be obtained by a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder by timely filing an appropriate claim for refund with the IRS. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders should consult their tax advisors regarding
their entitlement to benefits under an applicable income tax treaty. Dividends will also be subject to the discussion below under the heading &#147;FATCA.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dividends that are treated as effectively connected with a trade or business conducted by a <FONT STYLE="white-space:nowrap">non-U.S.</FONT>
holder within the United States and, if an applicable income tax treaty so provides, that are attributable to a permanent establishment or a fixed base maintained by the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder within the United
States, are generally exempt from the 30% withholding tax if the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder satisfies applicable certification and disclosure requirements prior to the distribution date (generally including provision of
a valid IRS Form <FONT STYLE="white-space:nowrap">W-8ECI</FONT> (or applicable successor form) certifying that the dividends are effectively connected with the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s conduct of a trade or
business within the United States). However, such U.S. effectively connected income, net of specified deductions and credits, is taxed at the same graduated U.S. federal income tax rates applicable to U.S. persons (as defined in the Code). Any U.S.
effectively connected income received by a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder that is a corporation may also, under certain circumstances, be subject to an additional &#147;branch profits tax&#148; at a 30% rate or such lower
rate as may be specified by an applicable income tax treaty. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Gain on Sale, Exchange or Other Disposition of Our Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the discussion below regarding backup withholding and FATCA, in general, a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder
will not be subject to any U.S. federal income tax on any gain realized upon such <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s sale, exchange or other disposition of our common stock unless: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the gain is effectively connected with a U.S. trade or business of the
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder and, if an applicable income tax treaty so provides, is attributable to a permanent establishment or a fixed base maintained in the United States by such
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder, in which case the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder generally will be taxed at the graduated U.S. federal income tax rates applicable to U.S. persons (as defined in the
Code) and, if the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder is a foreign corporation, the branch profits tax described above in &#147;Distributions on Our Common Stock&#148; also may apply; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder is a nonresident alien individual who is present in
the United States for 183 days or more in the taxable year of the disposition and certain other requirements are met, in which case the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder will be subject to a 30% tax (or such lower rate as may
be specified by an applicable income tax treaty) on the net gain derived from the disposition, which may be offset by U.S. source capital losses of the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder, if any; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our common stock constitutes a U.S. real property interest because we are, or have been, at any time during the
five-year period preceding such disposition (or the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s holding period, if shorter) a &#147;U.S. real property holding corporation.&#148; Generally, a corporation is a U.S. real property
holding corporation only if the fair market value of its U.S. real property interests equals or exceeds 50% of the sum of the fair market value of its worldwide real property interests plus its other assets used or held for use in a trade or
business. Although there can be no assurance, we do not believe that we are, or have been, a U.S. real property holding corporation, or that we are likely to become one in the future. Even if we are or become a U.S. real property holding
corporation, provided that our common stock is regularly traded, as defined by applicable U.S. Treasury Regulations, on an established securities market, our common stock will be treated as a U.S. real property interest only with respect to a <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder that holds more than 5% of our outstanding common stock, directly or indirectly, actually or constructively, during the shorter of the <FONT STYLE="white-space:nowrap">5-year</FONT> period ending on
the date of the disposition or the period that the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder held our common stock. If we are a U.S. real property holding corporation and either our common stock is not regularly traded on an
established securities market or a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder holds, or is treated as holding, more than 5% of our outstanding common stock, directly or indirectly, during the applicable testing period, such <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder will generally be taxed on any gain in the same manner as gain that is effectively connected with the conduct of a U.S. trade or business, except that the branch profits tax generally will not apply.
If we are a U.S. real property holding corporation and our common stock is not regularly traded on an established securities market, a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s proceeds received on the disposition of our common
stock will also generally be subject to withholding at a rate of 15%. Prospective investors are encouraged to consult their own tax advisors regarding the possible consequences to them if we are, or were to become, a U.S. real property holding
corporation. No assurance can be provided that our common stock is or will in the future be regularly traded on an established securities market for purposes of the rules described above. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Backup Withholding and Information Reporting </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We must report annually to the IRS and to each <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder the gross amount of the dividends on our
common stock paid to such <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder and the tax withheld, if any, with respect to such dividends. A <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder will have to comply with specific certification
procedures to establish that the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder is not a U.S. person (as defined in the Code) in order to avoid backup withholding at the applicable rate with respect to dividends on our common stock. A <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder generally will not be subject to U.S. backup withholding with respect to payments of dividends on our common stock if it certifies its <FONT STYLE="white-space:nowrap">non-U.S.</FONT> status by
providing a valid IRS Form <FONT STYLE="white-space:nowrap">W-8BEN,</FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> or <FONT STYLE="white-space:nowrap">W-8ECI</FONT> (or applicable successor form), or
otherwise establishes an exemption; provided we do not have actual knowledge or reason to know such <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder is a U.S. person (as defined in the Code). Dividends paid to
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders subject to the U.S. withholding tax, as described above in &#147;Distributions on Our Common Stock,&#148; generally will be exempt from U.S. backup withholding. Information reporting and
backup withholding will generally apply to the proceeds of a disposition of our common stock by a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder effected by or through the U.S. office of any broker, U.S. or foreign, unless the <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder certifies its status as a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder and satisfies certain other requirements, or otherwise establishes an exemption. Generally, information reporting and
backup withholding will not apply to a payment of disposition proceeds to a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder where the transaction is effected outside the United States through a
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> office of a broker. However, for information reporting purposes, dispositions effected through a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> office of a broker with substantial U.S. ownership or
operations generally will be treated in a manner similar to dispositions effected through a U.S. office of a broker. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders should consult their tax advisors regarding the application of the
information reporting and backup withholding rules to them. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Copies of information returns may be made available to the tax authorities of the country in
which the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder resides or is incorporated under the provisions of a specific treaty or agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Backup withholding is not an additional tax. Any amounts withheld under the backup withholding rules from a payment to a <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder may be allowed as a credit against the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s U.S. federal income tax liability, if any, and may entitle such
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder to a refund, provided the required information is timely furnished to the IRS. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>FATCA </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Foreign Account Tax Compliance Act, or FATCA, generally imposes a U.S. federal withholding tax of 30% on dividends and, subject to the
proposed Treasury Regulations discussed below, the gross proceeds of a disposition of our common stock paid to a &#147;foreign financial institution&#148; and certain other <FONT STYLE="white-space:nowrap">non-U.S.</FONT> entities unless various
U.S. information reporting and due diligence requirements (generally relating to ownership by U.S. persons of interests in or accounts with those entities) have been satisfied, or an exemption applies. An intergovernmental agreement between the
United States and an applicable foreign country may modify these requirements. Under certain circumstances, a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder may be eligible for refunds or credits of any such taxes withheld. The U.S.
Treasury released proposed Treasury Regulations which, if finalized in their present form, would eliminate the federal withholding tax of 30% applicable to the gross proceeds of a sale or other disposition of our common stock. Taxpayers may
generally rely on the proposed regulations until final regulations are issued. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders should consult their tax advisers regarding the effects of FATCA on their investment in our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>THIS SUMMARY IS NOT INTENDED TO BE TAX ADVICE. EACH PROSPECTIVE INVESTOR SHOULD CONSULT ITS TAX ADVISOR REGARDING THE PARTICULAR U.S.
FEDERAL, STATE AND LOCAL AND <FONT STYLE="white-space:nowrap">NON-U.S.</FONT> TAX CONSEQUENCES OF PURCHASING, OWNING AND DISPOSING OF OUR COMMON STOCK. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc694036_9"></A>UNDERWRITING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company and the underwriters named below have entered into an underwriting agreement with respect to the securities being offered. Subject
to certain conditions, each underwriter has severally agreed to purchase the number of shares indicated in the following table. Goldman Sachs&nbsp;&amp; Co. LLC, Jefferies LLC, Cowen and Company, LLC, Evercore Group L.L.C. and Piper Sandler &amp;
Co. are the representatives of the underwriters. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="56%"></TD>

<TD VALIGN="bottom" WIDTH="22%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="22%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP>Underwriters</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">Number&nbsp;of&nbsp;Shares<BR>of&nbsp;Common&nbsp;Stock</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">Number of<BR><FONT STYLE="white-space:nowrap">Pre-funded&nbsp;Warrants</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Goldman Sachs&nbsp;&amp; Co. LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jefferies LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cowen and Company, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Evercore Group L.L.C.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Piper Sandler &amp; Co.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">UBS Securities LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Citizens JMP Securities, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters are committed to take and pay for all of the securities being offered, if any are taken,
other than the shares covered by the option described below unless and until this option is exercised. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters have an option to
buy up to an additional &#8195;&#8195;&#8195; shares of common stock from the Company to cover sales by the underwriters of a greater number of shares of common stock than the total number set forth in the table above. They may exercise that option
for 30 days. If any shares are purchased pursuant to this option, the underwriters will severally purchase shares of common stock in approximately the same proportion as set forth in the table above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table shows the per share and total underwriting discounts and commissions to be paid to the underwriters by the Company. Such
amounts are shown assuming both no exercise and full exercise of the underwriters&#146; option to purchase &#8195;&#8195;&#8195; additional shares of common stock. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Paid by the Company </U></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="40%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>Per Share of<BR>Common Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>No&nbsp;Exercise</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Full&nbsp;Exercise</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B><FONT STYLE="white-space:nowrap">Per&nbsp;Pre-Funded&nbsp;Warrant</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>No&nbsp;Exercise</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Full&nbsp;Exercise</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Per Share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Shares sold by the underwriters to the public will initially be offered at the initial public offering price
set forth on the cover of this prospectus. Any shares sold by the underwriters to securities dealers may be sold at a discount of up to $&#8195;&#8195;&#8195;&#8195; per share from the initial public offering price. After the initial offering of the
shares, the representatives may change the offering price and the other selling terms. The offering of the shares by the underwriters is subject to receipt and acceptance and subject to the underwriters&#146; right to reject any order in whole or in
part. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company, its officers and directors have agreed with the underwriters, subject to certain exceptions, not to dispose of or
hedge any of their common stock or securities convertible into or exchangeable for shares of common stock during the period from the date of this prospectus continuing through the date 60 days after the date of this prospectus, except with the prior
written consent of Goldman Sachs &amp; Co. LLC. This agreement does not apply to any existing employee benefit plans. See &#147;Shares Available for Future Sale&#148; for a discussion of certain transfer restrictions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The restrictions described in the immediately preceding paragraph do not apply to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the sale of shares of our common stock to the underwriters pursuant to the terms of the underwriting agreement;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the issuance by us of common stock upon the exercise of options outstanding as of the date of this prospectus
supplement or issued after the date of this prospectus supplement pursuant to our equity plans that are described herein; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the issuance by us of common stock upon the conversion or exchange of convertible or exchangeable securities
outstanding as of the date of this prospectus supplement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the issuance of by us of common stock upon the exercise of warrants outstanding as of the date of this prospectus
supplement that are described herein; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the issuance by us of shares of common stock, stock options, restricted stock awards or securities convertible
into, exchangeable for or that represent the right to receive shares of common stock, in each case pursuant to our equity plans that are described herein, or pursuant to Nasdaq permitted inducements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(i) the issuance by us of shares of capital stock or securities convertible into, exchangeable for or that
represent the right to receive capital stock in connection with any joint venture, commercial or collaborative relationship or the acquisition or license by us of the securities, businesses, property or other assets of another person or entity, or
(ii)&nbsp;the filing of any registration statement on Form <FONT STYLE="white-space:nowrap">S-8</FONT> relating to the securities granted or to be granted pursuant to (A)&nbsp;our equity plans that are described herein or (B)&nbsp;any assumed
employee benefit plan contemplated by clause (i), provided, that the aggregate number of shares of common stock that we may sell or issue or agree to sell or issue pursuant to clauses (i)&nbsp;and (ii) shall not exceed 5% of the total number of our
shares of common stock outstanding as of the date of this prospectus supplement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the issuance by us of rights, common stock, preferred stock or securities convertible into, exchangeable for or
that represent the right to receive preferred stock or common stock in connection with any rights plan adopted by us; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">transfers of shares of common stock or securities convertible into or exchangeable for shares of common stock
(i)&nbsp;as a <I>bona fide</I> gift or gifts or by will, other testamentary document or intestate succession, (ii)&nbsp;to any trust for the direct or indirect benefit of such party or the immediate family of such party, provided that the trustee of
the trust agrees to be bound in writing by the restrictions set forth in such agreement, and provided further that any such transfer shall not involve a disposition for value, (iii)&nbsp;pursuant to any order or settlement agreement approved by any
court of competent jurisdiction, (iv)&nbsp;to any corporation, partnership, limited liability company or similar entity of which 100% of the beneficial ownership interests are owned by such party or the immediate family of such party, (v)&nbsp;to
such party&#146;s affiliates, shareholders, members, partners, subsidiaries or to any investment fund or other entity controlled or managed by such party, or (vi)&nbsp;by operation of law, including pursuant to a domestic order or negotiated divorce
settlement, provided that (A)&nbsp;in the case of any transfer pursuant to clauses (i), (iii), (iv), (v), and (vi), each transferee agrees in writing to be bound by the restrictions set forth in such agreement, (B)&nbsp;in the case of any transfer
pursuant to clauses (iii), (iv), (v), and (vi), no public announcement or filing by any party under the Exchange Act, shall be required or voluntarily made in connection with such transfer, (C)&nbsp;in the case of any transfer pursuant to clauses
(i), (iii), (iv), (v), and (vi), any such transfer shall not involve a disposition for value and (D)&nbsp;in the case of any transfer pursuant to clause (i), no filing under the Exchange Act or other public filing, report or announcement shall be
voluntarily made, and if any such filing, report or announcement shall be legally required during the restricted period, such filing, report or announcement shall clearly indicate in the footnotes thereto the circumstances of such transfer or
distribution and that the transferee has agreed to be bound by the restrictions set forth in such agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the establishment of a new trading plan pursuant to Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> under the
Exchange Act providing for dispositions or sales of shares of common stock; provided that such plan does not permit dispositions or sales during the restricted period and no public announcement or filing under the Exchange Act regarding the
establishment of such plan shall be required or voluntarily made during the restricted period; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the exercise of options or other stock-based awards to purchase shares of our common stock or the vesting of
restricted stock or other stock-based awards outstanding as of the date of this prospectus supplement or granted under equity incentive plans in effect as of the date of this prospectus supplement or described herein and expiring during the
restricted period; provided that the underlying shares of our common stock continue to be subject to the terms of such agreement, and provided further that any filing under Section&nbsp;16(a) of the Exchange Act made in connection with such transfer
shall clearly indicate in the footnotes thereto that the filing relates to the circumstances described herein; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">transfers of shares of common stock pursuant to a bona fide third party tender offer, merger, consolidation or
other similar transaction made to holders of our common stock involving a change of control; provided that in the event that the tender offer, merger, consolidation or other such transaction is not completed during the restricted period, such shares
of common stock shall remain subject to the foregoing restrictions during such period; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in the case of lockup agreements signed by officers, the repurchase or forfeiture of shares of common stock in
connection with termination of such officer&#146;s employment with us; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the settlement of options, restricted stock or other stock-based awards expiring during the restricted period on
a &#147;net&#148; or &#147;cashless&#148; basis or any other withholding of shares of our common stock by us upon vesting and/or settlement of options, restricted stock or other stock-based awards expiring during the restricted period to satisfy tax
obligations; provided that (x)&nbsp;the underlying shares of commons stock received by such <FONT STYLE="white-space:nowrap">lock-up</FONT> party shall continue to be subject to the restrictions set forth in such agreement, (y)&nbsp;any such settled
or withheld shares are surrendered to us in the net or cashless exercise and (z)&nbsp;that any filing under Section&nbsp;16(a) of the Exchange Act made in connection with such transfer or disposition shall clearly indicate in the footnotes thereto
the nature of the transfer or disposition. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the offering, the underwriters may purchase and sell
shares of common stock in the open market. These transactions may include short sales, stabilizing transactions and purchases to cover positions created by short sales. Short sales involve the sale by the underwriters of a greater number of shares
than they are required to purchase in the offering, and a short position represents the amount of such sales that have not been covered by subsequent purchases. A &#147;covered short position&#148; is a short position that is not greater than the
amount of additional shares for which the underwriters&#146; option described above may be exercised. The underwriters may cover any covered short position by either exercising their option to purchase additional shares or purchasing shares in the
open market. In determining the source of shares to cover the covered short position, the underwriters will consider, among other things, the price of shares available for purchase in the open market as compared to the price at which they may
purchase additional shares pursuant to the option described above. &#147;Naked&#148; short sales are any short sales that create a short position greater than the amount of additional shares for which the option described above may be exercised. The
underwriters must cover any such naked short position by purchasing shares in the open market. A naked short position is more likely to be created if the underwriters are concerned that there may be downward pressure on the price of the common stock
in the open market after pricing that could adversely affect investors who purchase in the offering. Stabilizing transactions consist of various bids for or purchases of common stock made by the underwriters in the open market prior to the
completion of the offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters may also impose a penalty bid. This occurs when a particular underwriter repays to the
underwriters a portion of the underwriting discount received by it because the representatives have repurchased shares sold by or for the account of such underwriter in stabilizing or short covering transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Purchases to cover a short position and stabilizing transactions, as well as other purchases by the underwriters for their own accounts, may
have the effect of preventing or retarding a decline in the market price of the Company&#146;s stock, and together with the imposition of the penalty bid, may stabilize, maintain or otherwise affect the market price of the common stock. As a result,
the price of the common stock may be higher than the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
price that otherwise might exist in the open market. The underwriters are not required to engage in these activities and may end any of these activities at any time. These transactions may be
effected on Nasdaq, in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market or otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company may enter into derivative transactions with third parties, or sell securities not covered by this prospectus to third parties in
privately negotiated transactions. In connection with those derivatives, the third parties may sell securities covered by this prospectus, including in short sale transactions. If so, the third party may use securities pledged by the Company or
borrowed from the Company or others to settle those sales or to close out any related open borrowings of stock, and may use securities received from the Company in settlement of those derivatives to close out any related open borrowings of stock.
The third party in such sale transactions will be an underwriter or will be identified in a post-effective amendment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company
estimates that the total expenses of the offering, excluding underwriting discounts and commissions, will be approximately $&#8195;&#8195;&#8195;. The underwriters have agreed to reimburse the Company for certain expenses in connection with the
offering in an amount not to exceed $&#8195;&#8195;&#8195;&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has agreed to indemnify the several underwriters
against certain liabilities, including liabilities under the Securities Act of 1933. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters and their respective affiliates are
full service financial institutions engaged in various activities, which may include sales and trading, commercial and investment banking, advisory, investment management, investment research, principal investment, hedging, market making, brokerage
and other financial and <FONT STYLE="white-space:nowrap">non-financial</FONT> activities and services. Certain of the underwriters and their respective affiliates have provided, and may in the future provide, a variety of these services to the
issuer and to persons and entities with relationships with the issuer, for which they received or will receive customary fees and expenses. Cowen and Company, LLC is the sales agent under the Sales Agreement. Under the Sales Agreement, we may offer
and sell, from time to time, shares of our common stock through Cowen and Company, LLC through an &#147;at the market offering,&#148; as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the ordinary course of their various business activities, the underwriters and their respective affiliates, officers, directors and
employees may purchase, sell or hold a broad array of investments and actively trade securities, derivatives, loans, commodities, currencies, credit default swaps and other financial instruments for their own account and for the accounts of their
customers, and such investment and trading activities may involve or relate to assets, securities and/or instruments of the issuer (directly, as collateral securing other obligations or otherwise) and/or persons and entities with relationships with
the issuer. The underwriters and their respective affiliates may also communicate independent investment recommendations, market color or trading ideas and/or publish or express independent research views in respect of such assets, securities or
instruments and may at any time hold, or recommend to clients that they should acquire, long and/or short positions in such assets, securities and instruments. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>European Economic Area </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In relation to
each EEA Member State (each a &#147;<B>Relevant Member State</B>&#148;), no shares of our common stock have been offered or will be offered pursuant to this offering to the public in that Relevant Member State prior to the publication of a
prospectus in relation to the shares which has been approved by the competent authority in that Relevant Member State or, where appropriate, approved in another Relevant Member State and notified to the competent authority in that Relevant Member
State, all in accordance with the Prospectus Regulation, except that the shares of our common stock may be offered to the public in that Relevant Member State at any time: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to any legal entity which is a qualified investor as defined under Article 2 of the Prospectus Regulation;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to fewer than 150 natural or legal persons (other than qualified investors as defined under Article 2 of the
Prospectus Regulation) subject to obtaining the prior consent of the representative for any such offer; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in any other circumstances falling within Article 1(4) of the Prospectus Regulation, </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">provided that no such offer of shares of our common stock shall require the Company and/or Selling
Shareholders or any Bank to publish a prospectus pursuant to Article 3 of the Prospectus Regulation or supplement a prospectus pursuant to Article 23 of the Prospectus Regulation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the purposes of this provision, the expression an &#145;offer to the public&#146; in relation to shares of our common stock in any
Relevant Member State means the communication in any form and by any means of sufficient information on the terms of the offer and any shares of our common stock to be offered so as to enable an investor to decide to purchase any shares, and the
expression &#147;Prospectus Regulation&#148; means Regulation (EU) 2017/1129. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each person in a Relevant Member State who receives any
communication in respect of, or who acquires any shares of our common stock under, this offering contemplated hereby will be deemed to have represented, warranted and agreed to and with each of the Underwriters and their affiliates and the Company
that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">it is a qualified investor within the meaning of the Prospectus Regulation; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in the case of any shares acquired by it as a financial intermediary, as that term is used in Article 5 of the
Prospectus Regulation, (i)&nbsp;the shares acquired by it in the Offering have not been acquired on a <FONT STYLE="white-space:nowrap">non-discretionary</FONT> basis on behalf of, nor have they been acquired with a view to their offer or resale to,
persons in any Relevant Member State other than qualified investors, as that term is defined in the Prospectus Regulation, or have been acquired in other circumstances falling within the points (a)&nbsp;to (d) of Article 1(4) of the Prospectus
Regulation and the prior consent of Goldman Sachs&nbsp;&amp; Co. LLC has been given to the offer or resale; or (ii)&nbsp;where the shares have been acquired by it on behalf of persons in any Relevant Member State other than qualified investors, the
offer of those shares to it is not treated under the Prospectus Regulation as having been made to such persons. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Company, the Underwriters and their affiliates, and others will rely upon the truth and accuracy of the foregoing representation, acknowledgement and agreement. Notwithstanding the above, a person who is not a qualified investor and who has notified
Goldman Sachs&nbsp;&amp; Co. LLC of such fact in writing may, with the prior consent of Goldman Sachs&nbsp;&amp; Co. LLC, be permitted to acquire shares of common stock in this offering. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>United Kingdom </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Prospectus and any
other material in relation to shares of common stock described herein is only being distributed to, and is only directed at, and any investment or investment activity to which this Prospectus relates is available only to, and will be engaged in only
with persons who are (i)&nbsp;persons having professional experience in matters relating to investments who fall within the definition of investment professionals in Article 19(5) of the FPO; or (ii)&nbsp;high net worth entities falling within
Article 49(2)(a) to (d)&nbsp;of the FPO; (iii)&nbsp;outside the UK; or (iv)&nbsp;persons to whom an invitation or inducement to engage in investment activity (within the meaning of Section&nbsp;21 of the FSMA) in connection with the issue or sale of
any shares of common stock may otherwise lawfully be communicated or caused to be communicated, (all such persons together being referred to as &#147;<B>Relevant Persons</B>&#148;). The shares of common stock are only available in the UK to, and any
invitation, offer or agreement to purchase or otherwise acquire the shares common stock will be engaged in only with, the Relevant Persons. This Prospectus and its contents are confidential and should not be distributed, published or reproduced (in
whole or in part) or disclosed by recipients to any other person in the UK. Any person in the UK that is not a Relevant Person should not act or rely on this Prospectus or any of its contents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No shares of common stock have been offered or will be offered pursuant to this offering to the public in the United Kingdom prior to the
publication of a prospectus in relation to the shares of common stock which has been approved by the Financial Conduct Authority, except that the shares of common stock may be offered to the public in the United Kingdom at any time: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to any legal entity which is a qualified investor as defined under Article 2 of the UK Prospectus Regulation;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to fewer than 150 natural or legal persons (other than qualified investors as defined under Article 2 of the UK
Prospectus Regulation), subject to obtaining the prior consent of the Global Coordinators for any such offer; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in any other circumstances falling within Section&nbsp;86 of the FSMA. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">provided that no such offer of the shares of common stock shall require the Company and/or any Underwriters or any of their affiliates to publish a prospectus
pursuant to Section&nbsp;85 of the FSMA or supplement a prospectus pursuant to Article 23 of the UK Prospectus Regulation. For the purposes of this provision, the expression an &#147;offer to the public&#148; in relation to the shares of common
stock in the United Kingdom means the communication in any form and by any means of sufficient information on the terms of the offer and any shares of common stock to be offered so as to enable an investor to decide to purchase or subscribe for any
shares of common stock and the expression &#147;UK Prospectus Regulation&#148; means Regulation (EU) 2017/1129 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each person in the UK who acquires any shares of common stock in this offering or to whom any offer is made will be deemed to have represented, acknowledged
and agreed to and with the Company, the Underwriters and their affiliates that it meets the criteria outlined in this section. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Canada </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The securities may be sold in Canada only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as
defined in National Instrument <FONT STYLE="white-space:nowrap">45-106</FONT> Prospectus Exemptions or subsection 73.3(1) of the Securities Act (Ontario), and are permitted clients, as defined in National Instrument
<FONT STYLE="white-space:nowrap">31-103</FONT> Registration Requirements, Exemptions, and Ongoing Registrant Obligations. Any resale of the securities must be made in accordance with an exemption form, or in a transaction not subject to, the
prospectus requirements of applicable securities laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Securities legislation in certain provinces or territories of Canada may provide a
purchaser with remedies for rescission or damages if this offering memorandum (including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit
prescribed by the securities legislation of the purchaser&#146;s province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser&#146;s province or territory of these rights or consult
with a legal advisor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to section 3A.3 of National Instrument <FONT STYLE="white-space:nowrap">33-105</FONT> Underwriting
Conflicts (NI <FONT STYLE="white-space:nowrap">33-105),</FONT> the underwriters are not required to comply with the disclosure requirements of NI <FONT STYLE="white-space:nowrap">33-105</FONT> regarding underwriter conflicts of interest in
connection with this offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Hong Kong </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares may not be offered or sold in Hong Kong by means of any document other than (i)&nbsp;in circumstances which do not constitute an
offer to the public within the meaning of the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Cap. 32 of the Laws of Hong Kong) (&#147;Companies (Winding Up and Miscellaneous Provisions) Ordinance&#148;) or which do not constitute an
invitation to the public within the meaning of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong) (&#147;Securities and Futures Ordinance&#148;), or (ii)&nbsp;to &#147;professional investors&#148; as defined in the Securities
and Futures Ordinance and any rules made thereunder, or (iii)&nbsp;in other circumstances which do not result in the document being a &#147;prospectus&#148; as defined in the Companies (Winding Up and Miscellaneous Provisions) Ordinance, and no
advertisement, invitation or document relating to the shares may be issued or may be in the possession of any person for the purpose of issue (in each case whether in Hong Kong or elsewhere), which is directed at, or the contents of which are likely
to be accessed or read by, the public in Hong Kong (except if permitted to do so under the securities </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
laws of Hong Kong) other than with respect to shares which are or are intended to be disposed of only to persons outside Hong Kong or only to &#147;professional investors&#148; in Hong Kong as
defined in the Securities and Futures Ordinance and any rules made thereunder. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Singapore </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus has not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, this prospectus and any other
document or material in connection with the offer or sale, or invitation for subscription or purchase, of the shares may not be circulated or distributed, nor may the shares be offered or sold, or be made the subject of an invitation for
subscription or purchase, whether directly or indirectly, to persons in Singapore other than (i)&nbsp;to an institutional investor (as defined under Section&nbsp;4A of the Securities and Futures Act, Chapter 289 of Singapore (the &#147;SFA&#148;))
under Section&nbsp;274 of the SFA, (ii)&nbsp;to a relevant person (as defined in Section&nbsp;275(2) of the SFA) pursuant to Section&nbsp;275(1) of the SFA, or any person pursuant to Section&nbsp;275(1A) of the SFA, and in accordance with the
conditions specified in Section&nbsp;275 of the SFA or (iii)&nbsp;otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA, in each case subject to conditions set forth in the SFA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Where the shares are subscribed or purchased under Section&nbsp;275 of the SFA by a relevant person which is a corporation (which is not an
accredited investor (as defined in Section&nbsp;4A of the SFA)) the sole business of which is to hold investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor, the securities (as
defined in Section&nbsp;239(1) of the SFA) of that corporation shall not be transferable for 6 months after that corporation has acquired the shares under Section&nbsp;275 of the SFA except: (1)&nbsp;to an institutional investor under
Section&nbsp;274 of the SFA or to a relevant person (as defined in Section&nbsp;275(2) of the SFA), (2) where such transfer arises from an offer in that corporation&#146;s securities pursuant to Section&nbsp;275(1A) of the SFA, (3)&nbsp;where no
consideration is or will be given for the transfer, (4)&nbsp;where the transfer is by operation of law, (5)&nbsp;as specified in Section&nbsp;276(7) of the SFA, or (6)&nbsp;as specified in Regulation 32 of the Securities and Futures (Offers of
Investments) (Shares and Debentures) Regulations 2005 of Singapore (&#147;Regulation 32&#148;) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Where the shares are subscribed or
purchased under Section&nbsp;275 of the SFA by a relevant person which is a trust (where the trustee is not an accredited investor (as defined in Section&nbsp;4A of the SFA)) whose sole purpose is to hold investments and each beneficiary of the
trust is an accredited investor, the beneficiaries&#146; rights and interest (howsoever described) in that trust shall not be transferable for 6 months after that trust has acquired the shares under Section&nbsp;275 of the SFA except: (1)&nbsp;to an
institutional investor under Section&nbsp;274 of the SFA or to a relevant person (as defined in Section&nbsp;275(2) of the SFA), (2) where such transfer arises from an offer that is made on terms that such rights or interest are acquired at a
consideration of not less than S$200,000 (or its equivalent in a foreign currency) for each transaction (whether such amount is to be paid for in cash or by exchange of securities or other assets), (3) where no consideration is or will be given for
the transfer, (4)&nbsp;where the transfer is by operation of law, (5)&nbsp;as specified in Section&nbsp;276(7) of the SFA, or (6)&nbsp;as specified in Regulation&nbsp;32. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Japan </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The securities have not been and
will not be registered under the Financial Instruments and Exchange Act of Japan (Act No.&nbsp;25 of 1948, as amended), or the FIEA. The securities may not be offered or sold, directly or indirectly, in Japan or to or for the benefit of any resident
of Japan (including any person resident in Japan or any corporation or other entity organized under the laws of Japan) or to others for reoffering or resale, directly or indirectly, in Japan or to or for the benefit of any resident of Japan, except
pursuant to an exemption from the registration requirements of the FIEA and otherwise in compliance with any relevant laws and regulations of Japan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc694036_10"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The validity of the securities offered by this prospectus supplement and the accompanying prospectus will be passed upon for us by Hogan
Lovells US LLP. Certain legal matters will be passed upon for the underwriters by Ropes&nbsp;
&amp; Gray LLP. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc694036_11"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The financial statements and management&#146;s assessment of the effectiveness of internal control over financial reporting (which is included in
Management&#146;s Report On Internal Control Over Financial Reporting) incorporated in this Prospectus by reference to the Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2023 have been so
incorporated in reliance on the report (which contains an explanatory paragraph relating to the Company&#146;s requirement for additional financing to fund future operations as described in Note 3 to the financial statements) of
PricewaterhouseCoopers LLP, an independent registered public accounting firm, given on the authority of said firm as experts in auditing and accounting. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc694036_12"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have on file with the SEC an effective &#147;shelf&#148; registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT>
relating to the securities that may be offered and sold hereunder. The full registration statement, including exhibits thereto, contains additional relevant information about us and these securities that, as permitted by the rules and regulations of
the SEC, we have not included in this prospectus supplement or the accompanying prospectus. You should read the full registration statement for further information about us and these securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any statement made in this prospectus supplement or the accompanying prospectus concerning the contents of any contract, agreement or other
document is only a summary of the actual contract, agreement or other document. If we have filed any contract, agreement or other document as an exhibit to the registration statement, then you should read the exhibit for a more complete
understanding of the document or matter involved. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We maintain a website at<I> www.madrigalpharma.com</I>. We make our SEC filings
available on our website, free of charge, as soon as reasonably practicable after such materials are filed with, or furnished to, the SEC. Information presented or accessed through our website is not incorporated into, or made a part of, this
prospectus supplement or the accompanying prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our SEC filings are available from the SEC&#146;s Internet site at<I>
http://www.sec.gov</I>, which contains reports, proxy and information statements and other information regarding issuers that file electronically with the SEC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, our common stock is listed on The Nasdaq Global Select Market and similar information concerning us can be inspected and copied
at the offices of The Nasdaq Stock Market, One Liberty Plaza, 165 Broadway, New York, NY 10006. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc694036_13"></A>INCORPORATION OF CERTAIN INFORMATION BY REFERENCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus supplement and the accompanying prospectus are part of a registration statement on <A HREF="http://www.sec.gov/Archives/edgar/data/1157601/000119312521177764/d174184ds3asr.htm">
<FONT STYLE="white-space:nowrap">Form&nbsp;S-3</FONT></A> filed by us with the SEC on June&nbsp;1, 2021 (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-256666).</FONT> This prospectus supplement and the accompanying prospectus do not contain all
of the information set forth in the registration statement, certain parts of which are omitted in accordance with the rules and regulations of the SEC. For further information about us and the securities offered by this prospectus supplement and the
accompanying prospectus, we refer you to the registration statement and its exhibits and schedules which may be obtained as described herein. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The SEC&#146;s rules allow us to &#147;incorporate by reference&#148; information into this
prospectus supplement and the accompanying prospectus, which means that we can disclose important information to you by referring you to another document filed separately with the SEC. The information incorporated by reference is considered to be
part of this prospectus supplement and the accompanying prospectus. This prospectus supplement and the accompanying prospectus incorporate by reference the documents listed below that we have previously filed with the SEC: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended
December&nbsp;31, 2023, as filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1157601/000162828024007376/mdgl-20231231.htm">February&nbsp;28, 2024</A>; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Definitive Proxy Statement on Schedule 14A filed on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1157601/000119312523128960/d447957ddef14a.htm">May&nbsp;1,
 2023</A>; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Current Reports on Form <FONT STYLE="white-space:nowrap">8-K,</FONT> as filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1157601/000119312524004269/d669791d8k.htm">January&nbsp;8,
 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1157601/000119312524049136/d757603d8k.htm">February&nbsp;
28, 2024</A> (filed under Item 5.02) and <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1157601/000119312524068170/d788116d8k.htm">March&nbsp;14, 2024</A>; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the description of our common stock contained in our Registration Statement on Form <FONT
STYLE="white-space:nowrap">8-A,</FONT> filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/1157601/000110465907004817/a07-2607_18a12b.htm">January&nbsp;
26, 2007</A>, as amended by the description of our common stock contained in <A HREF="http://www.sec.gov/Archives/edgar/data/1157601/000119312523045575/d437449dex43.htm">Exhibit&nbsp;4.3</A> to our Annual Report on Form
<FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended December&nbsp;31, 2022, as filed with the SEC on February&nbsp;23, 2023, and including any amendment or report filed for the purpose of updating such description.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also incorporate by reference into this prospectus supplement and the accompanying prospectus all documents filed by
us with the SEC pursuant to Sections 12(a), 13(c), 14 or 15(d) of the Exchange Act prior to the termination of any offering of securities made by this prospectus supplement and the accompanying prospectus. Nothing in this prospectus supplement or
the accompanying prospectus shall be deemed to incorporate information furnished but not filed with the SEC (including without limitation, information furnished under Item 2.02 or Item 7.01 of Form <FONT STYLE="white-space:nowrap">8-K,</FONT> and
any exhibits relating to such information). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any statement contained in this prospectus supplement or the accompanying prospectus or in a
document incorporated or deemed to be incorporated by reference in this prospectus supplement or the accompanying prospectus shall be deemed to be modified or superseded for purposes of this prospectus supplement or the accompanying prospectus to
the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference modifies or supersedes the statement. Any statement so modified or superseded shall not be deemed,
except as so modified or superseded, to constitute a part of this prospectus supplement and the accompanying prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You may request
a copy of the filings incorporated herein by reference, including exhibits to such documents that are specifically incorporated by reference, at no cost, by writing or calling us at the following address or telephone number: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Mardi C. Dier </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Chief Financial
Officer </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Madrigal Pharmaceuticals, Inc. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">200 Barr Harbor Drive, Suite 200 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">West Conshohocken, Pennsylvania 19428 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(267) <FONT STYLE="white-space:nowrap">824-2827</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Statements contained in this prospectus supplement and the accompanying prospectus as to the contents of any contract or other documents are
not necessarily complete, and in each instance investors are referred to the copy of the contract or other document filed as an exhibit to the registration statement, each such statement being qualified in all respects by such reference and the
exhibits and schedules thereto. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Madrigal Pharmaceuticals, Inc. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g694036g01t41.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Preferred Stock </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Warrants
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Debt Securities </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Units </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From time to time, we may offer
and sell, in one or more offerings, common stock, preferred stock, warrants, debt securities or units consisting of any combination of the other securities described in this prospectus. The preferred stock, warrants or debt securities may be
convertible into or exercisable or exchangeable for common stock, preferred stock or other securities. We may offer any combination of the securities, in separate series or classes and in amounts, at prices and on terms described in one or more
supplements to this prospectus. In addition, this prospectus may be used to offer securities for certain selling stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus describes
some of the general terms that may apply to the securities we and/or any selling stockholder may offer and sell and the general manner in which they may be offered. Each time we and/or any selling stockholder offer securities pursuant to this
prospectus, we will provide one or more supplements to this prospectus or free writing prospectuses that contain specific information about the offering and the terms of any securities being sold. You should carefully read this prospectus, any
prospectus supplement and any free writing prospectus, as well as any documents incorporated in any of the foregoing by reference, before you invest in our securities. This prospectus may not be used to sell our securities unless accompanied by a
prospectus supplement. The prospectus supplement or any related free writing prospectus may also add, update, supplement, change or clarify information contained in this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our common stock is traded on the NASDAQ Global Select Market under the symbol &#147;MDGL.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We or any selling stockholder may offer and sell our securities to or through one or more agents, underwriters, dealers or other third parties or directly to
one or more purchasers on a continuous or delayed basis. If agents, underwriters or dealers are used to sell our securities, we or any selling stockholder will name them and describe their compensation in a prospectus supplement. The price to the
public of our securities and the net proceeds we expect to receive from the sale of such securities will also be set forth in a prospectus supplement. We will not receive any proceeds from the sale of securities by selling stockholders. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>INVESTING IN OUR SECURITIES INVOLVES A HIGH DEGREE OF RISK. YOU SHOULD REVIEW CAREFULLY THE RISKS AND UNCERTAINTIES REFERENCED UNDER THE HEADING
&#147;</B><B><I><A HREF="#tx694096_5">RISK FACTORS</A></I></B><B>&#148; ON PAGE 4 OF THIS PROSPECTUS AS WELL AS THOSE CONTAINED IN THE APPLICABLE PROSPECTUS SUPPLEMENT AND ANY RELATED FREE WRITING PROSPECTUS, AND IN THE OTHER DOCUMENTS THAT ARE
INCORPORATED BY REFERENCE INTO THIS PROSPECTUS OR THE APPLICABLE PROSPECTUS SUPPLEMENT. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Neither the Securities and Exchange Commission nor any state
securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of this prospectus is June&nbsp;1, 2021. </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx694096_1">ABOUT THIS PROSPECTUS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx694096_2">WHERE YOU CAN FIND ADDITIONAL INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx694096_3">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx694096_4">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx694096_5">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx694096_6">ABOUT THE COMPANY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx694096_7">DESCRIPTION OF SECURITIES TO BE OFFERED</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx694096_8">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx694096_9">SELLING STOCKHOLDERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx694096_10">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx694096_11">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx694096_12">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>We are responsible for the information contained and incorporated by reference in this prospectus, in any accompanying
prospectus supplement, and in any related free writing prospectus we prepare or authorize. We have not authorized anyone to give you any other information, and we take no responsibility for any other information that others may give you. If you are
in a jurisdiction where offers to sell, or solicitations of offers to purchase, the securities offered by this documentation are unlawful, or if you are a person to whom it is unlawful to direct these types of activities, then the offer presented in
this document does not extend to you. The information contained in this document speaks only as of the date of this document, unless the information specifically indicates that another date applies. Our business, financial condition, results of
operations and prospectus may have changed since those dates. </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx694096_1"></A>ABOUT THIS PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus is part of an automatic shelf registration statement that we filed with the Securities and Exchange Commission, or the SEC, as a
&#147;well-known seasoned issuer&#148; as defined in Rule 405 under the Securities Act of 1933, as amended, or the Securities Act. Under this shelf registration process, we and/or selling stockholders may offer any security, or any combination of
the securities, described in this prospectus from time to time in one or more offerings. This prospectus only provides you with a general description of the securities we and/or selling stockholders may offer. Each time we and/or selling
stockholders offer a type or series of securities under this prospectus, we will provide a prospectus supplement that will contain more specific information about the specific terms of the offering. We may also authorize one or more free writing
prospectuses to be provided to you that may contain material information relating to these offerings. This prospectus may not be used to sell our securities unless accompanied by a prospectus supplement. Each such prospectus supplement and any free
writing prospectus that we may authorize to be provided to you may also add, update, supplement, change or clarify information contained in this prospectus or in documents incorporated by reference into this prospectus. We urge you to carefully read
this prospectus, any applicable prospectus supplement and any related free writing prospectus, together with the information incorporated herein by reference as described under the headings &#147;Where You Can Find Additional Information&#148; and
&#147;Incorporation of Certain Information by Reference&#148; before you invest in our securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Neither we nor any selling stockholder have authorized
anyone to provide you with information in addition to or different from that contained in this prospectus, any applicable prospectus supplement and any related free writing prospectus. We take no responsibility for, and can provide no assurances as
to the reliability of, any information not contained in this prospectus, any applicable prospectus supplement or any related free writing prospectus that we or a selling stockholder may authorize to be provided to you. This prospectus is an offer to
sell only the securities offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. You should assume that the information in this prospectus, any applicable prospectus supplement or any related free writing
prospectus is accurate only as of the date on the front of the document and that any information incorporated by reference is accurate only as of the date of the document incorporated by reference, regardless of the time of delivery of this
prospectus, any applicable prospectus supplement or any related free writing prospectus, or any sale of a security. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus contains summaries of
certain provisions contained in some of the documents described herein, but reference is made to the actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the
documents referred to herein have been filed, will be filed or will be incorporated by reference as exhibits to the registration statement of which this prospectus is a part, and you may obtain copies of those documents as described below under the
heading &#147;Where You Can Find Additional Information.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless otherwise mentioned or unless the context requires otherwise, throughout this
prospectus, any applicable prospectus supplement and any related free writing prospectus, the words &#147;Madrigal,&#148; &#147;we,&#148; &#147;us,&#148; &#147;our,&#148; the &#147;company&#148; or similar references refer to Madrigal
Pharmaceuticals, Inc. and its subsidiaries; and the term &#147;securities&#148; refers collectively to our common stock, preferred stock, warrants, debt securities, units consisting of any combination of the securities described in this prospectus,
and any combination of the foregoing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus and the information incorporated herein by reference contains references to trademarks, service
marks and trade names owned by us or other companies. Solely for convenience, trademarks, service marks and trade names referred to in this prospectus and the information incorporated herein, including logos, artwork, and other visual displays, may
appear without the <SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> or <SUP STYLE="font-size:75%; vertical-align:top">TM</SUP> symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest
extent under applicable law, our rights or the rights of the applicable licensor to these trademarks, service marks and trade names. We do not intend our use or display of other companies&#146; trade names, service marks or trademarks to imply a
relationship with, or endorsement or sponsorship of us by, any other companies. All trademarks, service marks and trade names included or incorporated by reference into this prospectus, any applicable prospectus supplement or any related free
writing prospectus are the property of their respective owners. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx694096_2"></A>WHERE YOU CAN FIND ADDITIONAL INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus is part of a registration statement that we have filed with the SEC. Certain information in the registration statement has been omitted from
this prospectus in accordance with the rules of the SEC. We are subject to the information requirements of the Securities Exchange Act of 1934, as amended, or the Exchange Act, and, in accordance therewith, file annual, quarterly and special
reports, proxy statements and other information with the SEC. The SEC maintains a website that contains these documents, which may be accessed through the SEC&#146;s Electronic Data Gathering, Analysis and Retrieval system, or EDGAR, via electronic
means, including the SEC&#146;s home page (<I>www.sec.gov</I>). </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx694096_3"></A>INCORPORATION OF CERTAIN INFORMATION BY
REFERENCE </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The SEC allows us to incorporate by reference much of the information we file with the SEC, which means that we can disclose important
information to you by referring you to those publicly available documents. The information that we incorporate by reference in this prospectus is considered to be part of this prospectus. Because we are incorporating by reference future filings with
the SEC, this prospectus supplement is continually updated, and those future filings may modify or supersede some of the information included or incorporated in this prospectus. You should review all of the SEC filings that we incorporate by
reference to determine if any of the statements in this prospectus or in any document previously incorporated by reference have been modified or superseded. Any statement so modified or superseded shall not be deemed, except as so modified or
superseded, to constitute a part of this prospectus. This prospectus incorporates by reference the documents listed below and any future filings we make with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act (in each case, other
than those documents or the portions of those documents not deemed to be filed) until the completion of the offering of securities described in this prospectus: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1157601/000119312521056164/d103755d10k.htm">Annual
 Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended December&nbsp;31, 2020, as filed with the SEC on February&nbsp;
25, 2021</A>, including the information specifically incorporated therein by reference from our <A HREF="http://www.sec.gov/Archives/edgar/data/1157601/000119312521144922/d107927ddef14a.htm">Definitive Proxy Statement on Schedule 14A, as filed with the
 SEC on April&nbsp;30, 2021</A>; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1157601/000119312521152386/d168724d10q.htm">Quarterly
 Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the fiscal quarter ended March&nbsp;31, 2021, as filed with the SEC on May&nbsp;6, 2021</A>; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001157601/000119312521164670/d168523d8k.htm">Current
 Report on Form <FONT STYLE="white-space:nowrap">8-K,</FONT> as filed with the SEC on May&nbsp;18, 2021</A>; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the description of our common stock contained in our Registration Statement on <A HREF="http://www.sec.gov/Archives/edgar/data/1157601/000110465907004817/a07-2607_18a12b.htm">Form
 <FONT STYLE="white-space:nowrap">8-A</FONT></A> filed with the SEC on January&nbsp;26, 2007, including any amendment thereto or report filed for the purpose of updating such descriptions, including but not limited to the description of our common
stock contained in <U>Exhibit 4.1</U> hereto and incorporated into this registration statement. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We do not, however, incorporate by
reference in this prospectus or any prospectus supplement any documents or portions thereof that are not deemed &#147;filed&#148; with the SEC, including any information furnished pursuant to Item 2.02 or Item 7.01 of our Current Reports on Form <FONT
STYLE="white-space:nowrap">8-K</FONT> unless, and except to the extent, specified in such reports. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You may request a copy of these filings, at no cost,
by contacting us, either orally or in writing, at: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Alex G. Howarth </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Chief Financial Officer </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Madrigal
Pharmaceuticals, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Four Tower Bridge </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">200 Barr Harbor Drive, Suite 200 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">West Conshohocken, Pennsylvania 19428 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(267) <FONT STYLE="white-space:nowrap">824-2827</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You may also access these documents, free of charge on the SEC&#146;s website at <I>www.sec.gov</I> or on
our website at <I>www.madrigalpharma.com</I>. The information contained in, or that can be accessed through, our website is not part of this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus is part of a registration statement we filed with the SEC. We have incorporated exhibits into this registration statement. You should read the
exhibits carefully for provisions that may be important to you. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Neither we nor any selling stockholder have authorized anyone to provide you with
information other than what is incorporated by reference or provided in this prospectus or any prospectus supplement. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx694096_4">
</A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus and the information incorporated by reference herein contain statements that
are not historical facts and are considered forward-looking within the meaning of Section&nbsp;27A of the Securities Act and Section&nbsp;21E of the Exchange Act. These forward-looking statements are based on our beliefs and assumptions and on
information currently available to us, but are subject to factors beyond our control. Forward-looking statements reflect management&#146;s current knowledge, assumptions, judgment and expectations regarding future performance or events; include all
statements that are not historical facts; and can be identified by terms such as &#147;allow,&#148; &#147;anticipates,&#148; &#147;be,&#148; &#147;believes,&#148; &#147;continue,&#148; &#147;could,&#148; &#147;demonstrates,&#148; &#148;design,&#148;
&#147;estimates,&#148; &#147;expects,&#148; &#147;forecasts,&#148; &#147;future,&#148; &#147;hopeful,&#148; &#147;goal,&#148; &#147;intends,&#148; &#147;may,&#148; &#147;might,&#148; &#147;plans,&#148; &#147;potential,&#148; &#147;predicts,&#148;
&#148;predictive,&#148; &#147;projects,&#148; &#147;seeks,&#148; &#147;should,&#148; &#147;will,&#148; &#147;will achieve,&#148; &#147;would&#148; or similar expressions and the negatives of those terms.&nbsp;We believe that it is important to
communicate our future expectations to our investors. However, there may be events in the future that we are not able to accurately predict or control and that may cause our actual results to differ materially from the expectations we describe in
our forward-looking statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investors are cautioned not to unduly rely on forward-looking statements because they relate to future events or our
future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of
activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements include, but are not limited to, statements about: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">anticipated or estimated future results, including the risks and uncertainties associated with our future
operating performance and financial position; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our possible or assumed future results of operations and expenses, business strategies and plans, capital needs
and financing plans, market trends, competitive position, industry environment and potential growth opportunities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our clinical trials, research and development activities, and the timing and results associated with the future
development of our lead product candidate, <FONT STYLE="white-space:nowrap">MGL-3196</FONT> (resmetirom); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our primary and secondary study endpoints for resmetirom, the potential for achieving such endpoints and
projections, including those regarding potential future <FONT STYLE="white-space:nowrap">non-alcoholic</FONT> steatohepatitis (&#147;NASH&#148;) resolution, safety, fibrosis treatment, cardiovascular effects and lipid treatment with resmetirom;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">optimal dosing levels for resmetirom and projections regarding potential NASH or nonalcoholic fatty liver disease
(&#147;NAFLD&#148;) patient benefits with resmetirom; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">market demand for and acceptance of our products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">research, development and commercialization of new products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtaining and maintaining regulatory approvals, including, but not limited to, potential regulatory delays or
rejections; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">risks associated with meeting the objectives of clinical studies, including, but not limited to our ability to
achieve enrollment objectives concerning patient number (including an adequate safety database) and/or timing for our studies, any delays or failures in enrollment, the occurrence of adverse safety events, and the risks of successfully conducting
trials that are substantially larger than our past trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">risks related to our ability to accomplish our business development objectives and realize the anticipated
benefit of any such transactions; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">assumptions underlying any of the foregoing. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Given these uncertainties, you should not place undue reliance on these forward-looking statements. These forward-looking statements speak only as of the date
on which the statements were made and are not guarantees of future performance. Except as may be required by applicable law, we do not undertake or intend to update any forward-looking statements after the date of this prospectus or the respective
dates of documents incorporated by reference herein that include forward-looking statements. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx694096_5"></A>RISK FACTORS
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You should carefully consider the risks described in the documents incorporated by reference in this prospectus and any prospectus supplement, as
well as other information we include or incorporate by reference into this prospectus and any applicable prospectus supplement, before making an investment decision. Our business, financial condition or results of operations could be materially
adversely affected by the materialization of any of these risks. The trading price of our securities could decline due to the materialization of any of these risks, and you may lose all or part of your investment. This prospectus and the documents
incorporated herein by reference also contain forward-looking statements that involve risks and uncertainties. Actual results could differ materially from those anticipated in these forward-looking statements as a result of certain factors,
including the risks described in the documents incorporated herein by reference, including our most recent annual report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> which is on file with the SEC and is incorporated herein by reference, and
other documents we file with the SEC that are deemed incorporated by reference into this prospectus. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx694096_6"></A>ABOUT THE
COMPANY </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a clinical-stage biopharmaceutical company pursuing novel therapeutics that target a specific thyroid hormone receptor pathway in the
liver, which is a key regulatory mechanism common to a spectrum of cardio-metabolic and fatty liver diseases with high unmet medical need. Our lead candidate, resmetirom, is
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">a&nbsp;first-in-class,&nbsp;orally</FONT></FONT> administered, small-molecule, liver-directed, thyroid hormone receptor (THR)-&szlig; selective agonist that is in currently in two
Phase 3 clinical studies, MAESTRO-NASH <FONT STYLE="white-space:nowrap">and&nbsp;MAESTRO-NAFLD-1,&nbsp;designed</FONT> to demonstrate multiple benefits across a broad spectrum of NASH&nbsp;and NAFLD patients. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We were incorporated in Delaware in September 2011. Our principal executive offices are located at 200 Barr Harbor Drive, Suite 200, West Conshohocken,
Pennsylvania 19428 and our telephone number at that address is (267) <FONT STYLE="white-space:nowrap">824-2827.</FONT> We maintain a website at <I>www.madrigalpharma.com</I>. The information on, or that can be accessed through, our website does not
constitute part of this prospectus, and you should not rely on any such information in making the decision whether to purchase our securities. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx694096_7"></A>DESCRIPTION OF SECURITIES TO BE OFFERED </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may offer shares of our common stock, preferred stock, warrants to purchase common stock or preferred stock, debt securities, in one or more series, as
either senior or subordinated debt or as senior or subordinated convertible debt, or units consisting of any combination of the other types of securities offered from time to time </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
in one or more offerings under this prospectus at prices and on terms to be determined at the time of any offering. This prospectus provides you with a general description of the securities we
and/or any selling stockholder may offer. Each time we and/or any selling stockholder offer a type or series of securities under this prospectus, we will provide a prospectus supplement and/or free writing prospectus that will describe the specific
amounts, prices and other important terms of the securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Common Stock.</I> We and/or any selling stockholder may issue and/or sell, as applicable,
shares of our common stock from time to time. Holders of shares of our common stock are entitled to one vote for each share held of record on all matters to be voted on by stockholders and do not have cumulative voting rights. Subject to the
preferences that may be applicable to any then outstanding shares of preferred stock, the holders of our outstanding shares of common stock are entitled to receive dividends, if any, as may be declared from time to time by our board of directors out
of funds legally available for dividend payments. The holders of our common stock have no preferences or rights of conversion, exchange, <FONT STYLE="white-space:nowrap">pre-emption</FONT> or other subscription rights. There are no redemption or
sinking fund provisions applicable to our common stock. In the event of our liquidation, dissolution or winding up, holders of our common stock will be entitled to share ratably in the net assets legally available for distribution to stockholders
after the payment of all of our debts and other liabilities, subject to the satisfaction of any liquidation preference granted to the holders of any outstanding shares of preferred stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Preferred Stock.</I> We may issue shares of our preferred stock from time to time, in one or more series. Our board of directors will determine the rights,
preferences and privileges of the shares of each wholly unissued series, and any qualifications, limitations or restrictions thereon, including dividend rights, voting rights, conversion rights, preemptive rights, terms of redemption or repurchase,
liquidation preferences, sinking fund terms and the number of shares constituting any series or the designation of any series. Convertible preferred stock will be convertible into our common stock or exchangeable for other securities. Conversion may
be mandatory or at the holder&#146;s option and would be at prescribed conversion rates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we sell any series of preferred stock under this prospectus,
we will fix the rights, preferences and privileges of the preferred stock of such series, as well as any qualifications, limitations or restrictions thereon, in the certificate of designation relating to that series. We will file as an exhibit to
the registration statement of which this prospectus is a part, or will incorporate by reference from reports that we file with the SEC, the form of any certificate of designation that describes the terms of the series of preferred stock we are
offering before the issuance of that series of preferred stock. We will describe the specific terms of a particular series of preferred stock in the prospectus supplement related to that series. We urge you to read the applicable prospectus
supplement and any free writing prospectus that we may authorize to be provided to you, as well as the complete certificate of designation, for complete information on any applicable series of preferred stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Warrants.</I> We may issue warrants for the purchase of common stock and/or preferred stock in one or more series. We may issue warrants independently or
together with common stock and/or preferred stock, and the warrants may be attached to or separate from these securities. We will describe the specific terms of any warrants we may offer in the prospectus supplement related to such warrants. We urge
you to read the applicable prospectus supplement and any free writing prospectus that we may authorize to be provided to you, as well as the complete warrant agreements and warrant certificates, for complete information on the terms of the warrants.
Forms of the warrant agreements and forms of warrant certificates containing the terms of the warrants being offered will be filed as exhibits to the registration statement of which this prospectus is a part or will be incorporated by reference from
reports that we file with the SEC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will evidence each series of warrants by warrant certificates that we will issue. Warrants may be issued under an
applicable warrant agreement that we enter into with a warrant agent. We will indicate the name and address of the warrant agent, if applicable, in the prospectus supplement relating to the particular series of warrants being offered. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Debt Securities.</I> We may issue debt securities, in one or more series, as either senior or subordinated debt or as senior or subordinated convertible
debt. The senior debt securities will rank equally with any other unsecured and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
unsubordinated debt. The subordinated debt securities will be subordinate and junior in right of payment, to the extent and in the manner described in this instrument governing the debt, to all
of our senior indebtedness. Convertible or exchangeable debt securities will be convertible into or exchangeable into our common stock or preferred stock. In this prospectus, we have summarized certain general features of the debt securities. The
applicable prospectus supplement will describe the specific debt securities being offered, the price at which they will be offered and other key terms including, as applicable, maturity dates, interest rates, denominations, redemption, conversion,
exchange, covenants and events of default. We urge you to read the applicable prospectus supplement and any free writing prospectus that we may authorize to be provided to you, as well as the complete indenture that contains the terms of the debt
securities, for complete information on the series of debt securities being offered. We will file as exhibits to the registration statement of which this prospectus is a part, the form of indenture and any supplemental agreements that describe the
terms of the series of debt securities we are offering before the issuance of the related series of debt securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may evidence each series of debt
securities we will issue by an indenture that we enter into with a trustee. We will indicate the name and address of the trustee, if applicable, in the prospectus supplement relating to the particular series of debt securities being offered. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Units.</I> We may issue, in one or more series, units consisting of any combination of the securities described in this prospectus. We will describe the
terms of the units we may offer in the prospectus supplement related to such units. The applicable prospectus supplement may describe the price or prices at which we will issue the units; the designation and terms of the units and of the securities
comprising the units, including whether and under what circumstances those securities may be held or transferred separately; any provisions for the issuance, payment, settlement, transfer or exchange of the units or of the securities comprising the
units; and whether the units will be issued in fully registered or global form. We urge you to read the applicable prospectus supplement and any free writing prospectus that we may authorize to be provided to you, as well as the complete unit
agreement that contains the terms of the units. We will file as exhibits to the registration statement of which this prospectus is a part, or will incorporate by reference from reports that we file with the SEC, the form of unit agreement and any
supplemental agreements that describe the terms of the series of units we are offering before the issuance of the related series of units. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may
evidence each series of units by unit certificates that we will issue. Units may be issued under a unit agreement that we enter into with a unit agent. We will indicate the name and address of the unit agent, if applicable, in the prospectus
supplement relating to the particular series of units being offered. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx694096_8"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except as described in any prospectus supplement or in any related free writing prospectus that we may authorize to be provided to you, we intend to use the
net proceeds received by us from the sale of the securities described in this prospectus for general corporate purposes. Unless otherwise set forth in a prospectus supplement, we will not receive any proceeds from the sale of securities by any
selling stockholder. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx694096_9"></A>SELLING STOCKHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Selling stockholders are persons or entities that, directly or indirectly, have acquired or will from time to time acquire, our securities. Such selling
stockholders may be parties to registration rights agreements with us, or we otherwise may have agreed or will agree to register their securities for resale. The initial purchasers of our securities, as well as their transferees, pledges, donees or
successors, all of whom we refer to as &#147;selling stockholders,&#148; may from time to time offer and sell our securities pursuant to this prospectus and any applicable prospectus supplement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The applicable prospectus supplement will set forth the name of each of the selling stockholders and the
number of securities beneficially owned by such selling stockholder that are covered by such prospectus supplement. The applicable prospectus supplement will also disclose whether any of the selling stockholders has held any position or office with,
has been employed by or otherwise has had a material relationship with us during the three years prior to the date of the applicable prospectus supplement. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx694096_10"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We and/or any selling stockholder may sell our securities from time to time in one or more transactions. We and/or any selling stockholder may sell our
securities to or through agents, underwriters, dealers, remarketing firms or other third parties or directly to one or more purchasers or through a combination of any of these methods of sale. In some cases, we and/or any selling stockholder or
dealer acting with us and/or any selling stockholder or on behalf of us and/or any selling stockholder may also purchase our securities and reoffer them to the public. We and/or any selling stockholder may also offer and sell, or agree to deliver,
our securities pursuant to, or in connection with, any option agreement or other contractual arrangement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Agents whom we designate may solicit offers to
purchase our securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We and/or any selling stockholder will name any agent involved in offering or selling our securities, and disclose any
commissions that we will pay to the agent, in the applicable prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless we and/or any selling stockholder indicate otherwise in the
applicable prospectus supplement, agents will act on a best efforts basis for the period of their appointment. Agents may be deemed to be underwriters under the Securities Act, of any of our securities that they offer or sell. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We and/or any selling stockholder may use an underwriter or underwriters in the offer or sale of our securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we and/or any selling stockholder use an underwriter or underwriters, we will execute an underwriting agreement with the underwriter or underwriters at the
time that we reach an agreement for the sale of our securities. We and/or any selling stockholder will include the names of the specific managing underwriter or underwriters, as well as the names of any other underwriters, and the terms of the
transactions, including the compensation the underwriters and dealers will receive, in the applicable prospectus supplement. The underwriters will use the applicable prospectus supplement, together with the prospectus, to sell our securities. The
underwriters may offer and sell our securities at a fixed price or prices which may be changed, at market prices prevailing at the time of sale, at prices related to such prevailing market prices or at negotiated prices, any of which may represent a
discount from the prevailing market price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may also, from time to time, authorize a dealer or agents to sell our securities. If we and/or any selling
stockholder use a dealer, we will sell our securities to the dealer, as principal. The dealer will then sell our securities to the public at varying prices that the dealer will determine at the time it sells our securities. We and/or any selling
stockholder will include the name of the dealer and the terms of the transactions with the dealer in the applicable prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We and/or any
selling stockholder may solicit directly offers to purchase our securities, and we may directly sell our securities to institutional or other investors. We and/or any selling stockholder will describe the terms of direct sales in the applicable
prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We and/or any selling stockholder may engage in at the market offerings into an existing trading market in accordance with Rule
415(a)(4) of the Securities Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We and/or any selling stockholder will indemnify agents, underwriters and dealers against certain
liabilities, including liabilities under the Securities Act. The terms and conditions of any indemnification will be described in the applicable prospectus supplement. Agents, underwriters and dealers, or their affiliates, may engage in transactions
with, or perform services for, us or our affiliates in the ordinary course of business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We and/or any selling stockholder may authorize agents and
underwriters to solicit offers by certain institutions to purchase our securities at the public offering price under delayed delivery contracts. If we and/or any selling stockholder use delayed delivery contracts, we will disclose that we are using
them in the prospectus supplement and will tell you when we will demand payment and when delivery of our securities will be made under the delayed delivery contracts. These delayed delivery contracts will be subject only to the conditions that we
describe in the prospectus supplement. We and/or any selling stockholder will describe in the applicable prospectus supplement the commission that underwriters and agents soliciting purchases of our securities under delayed delivery contracts will
be entitled to receive. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless otherwise specified in connection with a particular underwritten offering of our securities, the underwriters will not be
obligated to purchase offered securities unless specified conditions are satisfied, and if the underwriters do purchase any offered securities, they will purchase all offered securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with underwritten offerings of the offered securities and in accordance with applicable law and industry practice, the underwriters in certain
circumstances are permitted to engage in certain transactions that stabilize, maintain or otherwise affect the price of our securities, including the entry of stabilizing bids or syndicate covering transactions. If the underwriters create a short
position in our securities in connection with the offering (<I>i.e.,</I> if they sell more securities than are set forth on the cover page of the applicable prospectus supplement), the underwriters may reduce that short position by purchasing our
securities in the open market or as otherwise provided in the applicable prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The underwriters may also impose a penalty bid, whereby
selling concessions allowed to dealers participating in the offering may be reclaimed if the securities sold by them are repurchased in connection with stabilization transactions. In general, purchases of a security for the purpose of stabilization
or to reduce a short position could cause the price of the security to be higher than it might be in the absence of such purchases. The imposition of a penalty bid might also affect the price of our securities to the extent that it were to
discourage resales of our securities. The underwriters are not required to engage in these activities and may end any of these activities at any time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Such purchasers in the foregoing scenarios will be subject to the applicable provisions of the Securities Act and the Exchange Act and the rules and
regulations thereunder, including Rule <FONT STYLE="white-space:nowrap">10b-5</FONT> and Regulation M. Regulation M may restrict the ability of any person engaged in the distribution of the securities to engage in market-making activities with
respect to those securities. In addition, the anti-manipulation rules under the Exchange Act may apply to sales of our securities in the market. This may affect the marketability of our securities and the ability of any person to engage in
market-making activities with respect to our securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We and/or any selling stockholder may effect sales of securities in connection with forward
sale, option or other types of agreements with third parties. Any distribution of securities pursuant to any forward sale agreement may be effected from time to time in one or more transactions that may take place through a stock exchange, including
block trades or ordinary broker&#146;s transactions, or through broker-dealers acting either as principal or agent, or through privately-negotiated transactions, or through an underwritten public offering, or through a combination of any such
methods of ale, at market prices prevailing at the time of sale, prices relating to such prevailing market prices or at negotiated or fixed prices. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
specific terms of the <FONT STYLE="white-space:nowrap">lock-up</FONT> provisions, if any, in respect of any given offering will be described in the applicable prospectus supplement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In compliance with the guidelines of the Financial Industry Regulatory Authority, or FINRA, the maximum
consideration or discount to be received by any FINRA member or independent broker dealer may not exceed 8.0% of the aggregate amount of the securities offered by this prospectus. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx694096_11"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The validity of the securities being offered by this prospectus will be passed upon by Hogan Lovells US LLP, Washington, DC. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx694096_12"></A>EXPERTS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
financial statements and management&#146;s assessment of the effectiveness of internal control over financial reporting (which is included in Management&#146;s Report on Internal Control over Financial Reporting) incorporated in this prospectus by
reference to the Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2020 have been so incorporated in reliance on the report of PricewaterhouseCoopers LLP, an independent registered public
accounting firm, given on the authority of said firm as experts in auditing and accounting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:60pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>$500,000,000 </B></P>
<P STYLE="font-size:36pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g694036g01p01.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Shares of Common Stock </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants to Purchase&#8195;&#8195;&#8195;&#8195; Shares of Common Stock </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PROSPECTUS SUPPLEMENT </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:13.5pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:13.5pt">
<TD VALIGN="top"><B>Goldman&nbsp;Sachs&nbsp;&amp;&nbsp;Co.&nbsp;LLC</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Jefferies</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><B>TD&nbsp;Cowen</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>Evercore&nbsp;ISI</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>Piper&nbsp;Sandler</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" ALIGN="center">


<TR>

<TD WIDTH="25%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="58%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="15%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top" NOWRAP><B>UBS&nbsp;Investment&nbsp;Bank</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="right"><B>Citizens&nbsp;JMP</B></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>We have not authorized anyone to provide any information other than that contained or incorporated by reference in this prospectus supplement and
accompanying prospectus or any free writing prospectus that we or the underwriter provide you in connection with the offering. We take no responsibility for, and cannot provide any assurance as to the reliability of, any other information that
others may give you. We are not making an offer of these securities in any state where the offer is not permitted. You should not assume that the information contained in or incorporated by reference in this prospectus supplement and accompanying
prospectus is accurate as of any date other than the date on the front of this prospectus supplement. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>No action is being taken in any jurisdiction
outside the United States to permit a public offering of shares of our common stock or possession or distribution of this prospectus supplement in that jurisdiction. Persons who come into possession of this prospectus supplement in jurisdictions
outside the United States are required to inform themselves about and to observe any restrictions as to this offering and the distribution of this prospectus supplement applicable to that jurisdiction. </B></P>
<P STYLE="font-size:96pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:4.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g694036g01p01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g694036g01p01.jpg
M_]C_X  02D9)1@ ! 0$ E "4  #_[1F<4&AO=&]S:&]P(#,N,  X0DE-! 0
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M<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '
M      IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL=&EN4')O
M;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !     !       2<')I
M;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB<F)O;VP
M     %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP      $QB
M;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN=')B;V]L
M      !"8VMG3V)J8P    $       !21T)#     P    !29" @9&]U8D!O
MX            $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^
M      !"<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M          !2<VQT56YT1B-0>&Q 6             IV96-T;W)$871A8F]O
M; $     4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L
M=                %1O<"!5;G1&(U)L=                %-C;"!5;G1&
M(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P
M4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<
M#6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<
M #A"24T#[0      $ "4S,P  0 ! )3,S  !  $X0DE-!"8       X
M        /X   #A"24T$#0      !    %HX0DE-!!D       0    >.$))
M30/S       )           ! #A"24TG$       "@ !          $X0DE-
M _4      $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $
M,@    $ 6@    8       $ -0    $ +0    8       $X0DE- _@
M '   /____________________________\#Z     #_________________
M____________ ^@     _____________________________P/H     /__
M__________________________\#Z   .$))300(       0     0   D
M  )      #A"24T$1       $     (   )    "0      X0DE-!!X
M  0     .$))300:      -!    !@              20   4@    & &<
M,  Q '  ,  Q     0                         !              %(
M    20                     !                         !     !
M        ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q
M!     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M    20    !29VAT;&]N9P   4@    &<VQI8V5S5FQ,<P    %/8FIC
M 0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)
M1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U
M=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M         $QE9G1L;VYG          !"=&]M;&]N9P   $D     4F=H=&QO
M;F<   %(     W5R;%1%6%0    !        ;G5L;%1%6%0    !
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M300H       ,     C_P        .$))3001       ! 0 X0DE-!!0
M  0    $.$))300,      [B     0   *     D   !X   0X    [& !@
M ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L A  ," @("0@,
M"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,# P,# P,# P,
M# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.#@X.%!$,# P,#!$1# P,
M# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# S_P  1"  D * # 2(
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M_GWKJ9^]>8]?8_JV3UWJS#^BZ>^FBJ#H??\ 9],
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L
M0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@ 20%( P$1  (1 0,1 ?_$ !\
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M5XDE'^>$@#H9GBP'@[X+U>^7TW:[!RFL#!!22E2'*[,D4_) \Y/N6^1D=
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MTJ2M/-*DJ1^LD@I_TA(_?K*-\E""L?. ?)'D?E_Q'^/7YKZT&%Z]W]MO&?\
M<%AO_K/4+IIO!+]%[M_?E?X4&EA\7OTFI_[BG_\ 8YHCSTN/[!6V#_=A5?\
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MRMU0(0VCF1R6O[($J.8'8I7\,_7U%4XA+CBD(6M7%"UA"41R)XB$I3]OD !
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MMODR4R50)SPF5$&$G& ,$%?H^,F7.VZZQ"9+ES"C6F4A!EO2)*D(5AF(N);
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M$E0"95Q')7(]0$R,Z_#]'SU+-'KQK9I6Z^E4;.=.:'+HC:U\-B7A60O5<IQ
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M=T$X '_*?=<\>"?]4K _^_\  ?3\_KN'@=_35P_LT7_K-8SXR?T7;NOS5O\
MJC_D:SGZ/.M0V]ZS#D G6B1XY'/_ ,%8H21S]?'(^_/D>3QUR^-Q)W)31/\
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M6.LJ2IM;GZBEHD!0S@GD 3,$G5+\(MJUUXN%P\3]UH2]<+H"_9J=\%+5$P!
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M%3OCL[QR#Q[;V@V^EC<F[JA3-,A/Q+;=0KR16N_JJ\TH#B^P0DD])@8$CO\
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MI[KWMNS*MR&&OAGG/=]L E' Z[/&/:]YJ[JQ=Z5M533E)3Y5.A3RD]OE;"B
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M: FF>54&J2 KB0M742.N0,9,P1F-7MJQ4[MD%FKTBI:^'^%5 D<$R$D1(P"
M#$=001&J!-7OT?#.F\CDN:)ZQXN_A\N1(=C5FHU99-7-4TMWXF/#,ZAAV<6V
M^%;);$]4&ND.*': HCCK;K9XXI^#9I[M;JBI=294Z%-$#I!42DP?O)GIC)UC
M]Q\'GA4^9;K@6V3@-R4$Y$]#[S$$Y[F1K9]%/T>QZ-=P;+7?62NE4T1]E]['
M-.J61&<M62H.NPW[^X0P]!2N00WWLU4SELCN(\'KBNOC8XZT\W9[13T;JI"7
M2@1B0%"!! D>X,]8P>NV>$'%YE=SN;KS0P6P5&.Y'J,XZE1ZF"0>TM=X'HJZ
M5ZVPL/L=$+BIT;R##\6AXDU6II$2\8R"LKOFA2;5+!9EL748<^Y;#XZ3+ ^=
M*O*NJ]M7Q9O-B=?^.'Y08?)*T.2HB)F,?=,GWP3G4[N+POMUS99-N+=&^@ <
MB" >TS,R8ZQ(S$8U+OTW=J>J.S[1"=I7J;G-3F[[.4VEI1/4<BX?KJVEF\&-
M7LM74>,[#+0!"(L?F"R >U0ZI^\]Q4^Z+O\ E.FI&Z,/ <VT )$_6!)^LC'<
M]S:=G6"MV[;30UE3\062/+@\L8G!B)(!Q,@QB)TY.\G9;I9O4P"-A6I L*V?
M1S'[3%<HIW6TVV/6DB/\.N2TU)2Y#G1'F/\ G<64V4.H!91P^#QX;9W1<MJU
MOQ5N</!T?G$+*H($]9&(R),?[M=&Y=L4.YZ9IFM04N4Y/EN-A)()B1@9! )
M]\Z'VS7]'PUJCW#[>#:UZ=VV/*=<,)_**>]JK+V_/<'XU7&NH(6. GM2[SS]
MN>MK8\<J93:17VKS%=TQ))@"(4,_AU!Z:QVH\';B'.-)7H2UC(40/H9)]L3R
M,9@SG3ZZ'?H_E11RE7&N>JT3)GHL=YR#BN&U4JLHWK#X5[X-^TNIJTV<B+&=
M^=R%$B0Y#A\F7R.H>[>-=2^D(M-L11.'_*J3Q[=B  1)B9Q(ZP=2UN\'VD3^
M4KF[41V"R8(_& .^8^_&MSVG^B[ENW7<9IOK!8:X8ODD? K:3<+QV'CTZ).L
M8ST*5!2RT^[+>#2$*FL+]U0X'"5=QY'7%N;Q:_C'8WK8+3Y2*FGX*J/,/ *F
M8Y1QG$@',1VUW;<\,';%=V;@NL;=--QAM*B5@)G[/6#T.(D@@#5Y^:Y#B&0.
MW&BZ,PH8>>Y-@]Q,@8Z_/C&\%.XU^%KNA4*=$EZL8DR6FW'4LEM#JT-K6E2@
M.L@I [3N-5OEN*135((7Q/$$&>H 'L,__P U.M2W54[M!YB$O55*I(D@$@I(
M*HF8[G(R#(!C5'NS?T6LRVP[B=+]:;76C'LGA8!(L79%)!QB=!DSVIV-6V/C
MVI+\MU#"T.SDNJ"_/#2B4GM/.M[G\61N';[UC3:TL\Z8)#WF")!'TB#$=\'M
MK,-O>&2K)>6+JNJ9<2FIY^6DJ4H) @2D@^X,B),D$F=$1(\)0%+2D(5X^9/S
M>>#R>?'DE/U///!'TYQGO'?V[_LUKVFYU&U6T^THK:ZYU(S"DPRFN;ZHQ6LL
M<AGQJZ)-R"]?,:II8S\HAN3,M9 +$>,TXM]Q[EEIM:D\=>S%)452REAMQQ2$
M\E)0A2B$CJH@ P/J8^\=1SOU=/2I2I]QMM*SP2IQ:4 K,P$DD2K$P)/T,Z@7
MZDFQ>[WVX-IQB]!GE;@KF%Y5+R-Z385+MJF>Q,IW*H1&&8[[2FNWXI+G>O@
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M65;E2[DRE?-@9'^2!(R3,P)DGJ<L-8MNVC;M!^3;3;::F83GTI0EQ,]C48@
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MU?*L;-Q'GY6YMG&K8L,D@<A4:8. .0.?-MM/A'5.D.7*O++9F6DL*2KIUXJ
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M"20#@G/Z@$Y$F9U'W5IO>MN!TBVR:)'9#JO@;>DV<Z466=91?R*AR%(9PV5
MB_$8NW E2'I]>XS'_$;1^S37/PRDMM0IW''4];FMIVJXWNY)W32.!VEJTLMH
M8*BZ:J0I*$S*U>Z4 ]08P=1%>UNFY6VTVU6VWFRU5)4XXIVC"6P#(4HER$#N
M2HA(Z?02DU:Q?</MV]0?(MS.![=M0=P.!ZH:$U>G4R-IZ(";G%KN@OV;1IRR
M1:RH4)4*Q)BH*(\TNH9:D$CMBM=U;HE62Z;51;:Z[TML?H:OFRDLK4MQ).5)
M23)!&)3CN29,6"II[Y;]S_E*DMSURIZBE4AP_$-M)03) 4H@@$?JF>N!K?\
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ML?N+2IN'RZ\AD/X]9E+8=@-L-6^WU3U0SNVAH4)JY>IJEE2V*]L9"PE9X)&
M# F)')))U/;A1=;K3-LG;#M2XW2_R6I^+;9?HG#DI"OF<(.0),P)"L V!; L
M&UDT]VCZ*X?KU,M++4^FQ5#-^JZD29UQ#0N1+?J*FVG3DF5+M:>I?AU<R2ZZ
M5NR( <<DJ+G JFZZBW55]KW;4A**-Q0*.$%LX@E*D^E0, X[S.K1M=BNIK+0
MMW$K-4A)YAP%+B1. H* (,=C],8Q,.5!8EM^W*CM26E([%M/MEU"DGD=JD+0
MII?C\EH\@\?Q, A:FR%H6MIW/K;)Q]T=(QT]L:G%MH<24+;;=;Q*'0(,= 0H
MGO\ ^^H*ZH^F;LDU>F2[?+MO>'HNIREO2[;%T3\(GRY;QY7+F/8C+I!,D?D9
M$QMUP ?N\'JU6[?6ZK4GRZ.\U#:1^NDO#V^U,R/<Q[1TU5+CL;:UTE=3:&E*
M))_-K+!S$_+Q'8=I]I$Z:W'O1OV 8]8MV*-#W+=;)*VH]_G.=W$ N?4+>KYE
M^J*^GCP6Y;4@$^/I]))[Q.WF^WQ5=2G)REI()_ @@?=!/UR=<;'AQM.G="TV
MXN]/YUPJ$@]9G[L]( QC5BN%:?X=IQC=9A^"8O3XCC%+%3#JJ/'JV-4U<&,D
M@-MQ(<)EIAGQ^^I*6W/J2?F/%*J:RJK7E5%54.U+RC)<?4I2B>T\NWW??C5P
MIJ.EHV@Q3,-T[0^PRD)&<&(@DP!].@&!K=^#[7'!Y]OCC\^>WZ<??KFUU:^^
MC1I=&C2Z-&ET:-+HT:71HTNC1I=&C2Z-&ET:-+HT:71HTNC1I=&C2Z-&ET:-
M+HT:71HTNC1I=&C2Z-&ET:-+HT:71HTNC1I=&C2Z-&ET:-+HT:71HTNC1I=&
MC2Z-&ET:-+HT:71HTNC1I=&C2Z-&ET:-+HT:71HTNC1I=&C2Z-&ET:-+HT:_
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g694036g01t41.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g694036g01t41.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1F^4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &:*^96(X0DE-! 0      $0< 5H  QLE1QP"   " /\< E  "')R,CDS
M-S0X' (% "--:6-R;W-O9G0@5V]R9" M($U$1TP@+2!3+3-!4U(N9&]C>#A"
M24T$)0      $ >XX1' SA%C#<$UF-O=KMLX0DE-!#H      .4    0
M 0      "W!R:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT965N
M=6T     26YT90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP
M"W!R:6YT97).86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC
M    # !0 '( ;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P
M 0    !";'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"
M24T$.P     "+0   !     !       2<')I;G1/=71P=71/<'1I;VYS
M%P    !#<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#
M<FY#8F]O;       0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O
M;       16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $
M      !21T)#     P    !29" @9&]U8D!OX            $=R;B!D;W5B
M0&_@            0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M              !";&0@56YT1B-2;'0               !2<VQT56YT1B-0
M>&Q 5\            IV96-T;W)$871A8F]O; $     4&=0<V5N=6T
M4&=0<P    !09U!#     $QE9G15;G1&(U)L=                %1O<"!5
M;G1&(U)L=                %-C;"!5;G1&(U!R8T!9            $&-R
M;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<
M    #&-R;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG
M          MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $ .__C4
M @ " [_^-0 "  (X0DE-!"8       X             /X   #A"24T$#0
M    !    '@X0DE-!!D       0    >.$))30/S       )           !
M #A"24TG$       "@ !          (X0DE- _4      $@ +V9F  $ ;&9F
M  8       $ +V9F  $ H9F:  8       $ ,@    $ 6@    8       $
M-0    $ +0    8       $X0DE- _@      '   /__________________
M__________\#Z     #_____________________________ ^@     ____
M_________________________P/H     /__________________________
M__\#Z   .$))300(       0     0   D    )      #A"24T$'@
M!      X0DE-!!H      S4    &              !*   !10         !
M                          $              44   !*
M          $                         $     $       !N=6QL
M @    9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
M          !,969T;&]N9P          0G1O;6QO;F<   !*     %)G:'1L
M;VYG   !10    9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V4
M   2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P         &
M;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9
M  !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J
M8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F=&QO
M;F<          $)T;VUL;VYG    2@    !29VAT;&]N9P   44    #=7)L
M5$585     $       !N=6QL5$585     $       !-<V=E5$585     $
M      9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O; $
M   (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /15-L
M:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%
M4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N=6T
M   115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG
M          IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N
M9P         +<FEG:'1/=71S971L;VYG       X0DE-!"@       P    "
M/_         X0DE-!!$       $! #A"24T$%       !     0X0DE-! P
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MQ $_   !!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!
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MR@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                        _^%
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M 0$! 0$!_\  $0@ 2P%( P$1  (1 0,1 ?_$ !\   $$ @,! 0
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M OSK.;'AL- CXY7)+86I7P$(0%+6M24I0HG@ZE374M(%-1/%'WMVKW.HRWR
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M ,%V7OY \\<:D>MQ2$K62.&T!P$\)"N?+E)/'P!PD>7_ .[D']8^,G!'.0H
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MQ3TB,60H#CO4'(7N![OAQD D\\ZLGISU.KZBOALMZ<S+,PCAGE[5=')P%9@
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M4TSN4(92&4H6.03D$D '/&=;M33=0=I0O+.*Z.GDC>%F8F6,I(N&+!RZJ,'
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MG69".YF1>XJC >R *26)'.=3GI]U0N N$%HO;F:&9EACGEP)(23@%VP&=02
M>XD@# P  "XF' Z@+!!2H\I(^Q! (X/YCY^#^G'2L_Q!(/T(.#^\:9H$'M(.
M05R#\P>T@_K&@M_7\_UWL5_V!8A_OIL3IO\ H)_-F\_VF7^ZIM*5UN_G-2?V
M2+^,FB2?2P_U >U[_9?5_P#GK/I>.I/\][__ &J/_A8-,!TY_F=9_P#8J/\
MBY]11]5W9,L6VN]6P98,3Z2RRR]B-J!)E$Q(%$EX \CQ95;/(2O\)+B7/NA!
M">=<;T4^P6>*4@%3+4QJ>7R5:,'G@=ISCW'/U'Z.?D>[5BF?<&ZJJ$%X9(*"
M@E9<=B%':I*'CN!D"A^>#&HS["G-MOW%^*$EQ2EI0&4 ^:O+A*4M@<DJ5RE+
M:!]W.$#X/2\I&S2+&@,@9NQ.PY(D)PH.#D@)\&.<D>,Z>R>98(9)Y&")%$\S
MN>0 BEB3R!X!)SSCG\+(.X::G1W;#J?MZB+1'R;+X[>P-B(8)2XCZQ:Y42%(
M(')0J<ZM+:7.5>Q5,\#Q4.KEW5.FV]FVG;"OBKKU%56C/Q+'([3]K$<C)? \
M  :4;IC2OU%ZN;IZBU"$6ZRS+:K,".Y)/13T'>,D 9_1EBRY^.1@>,C33=FF
ME8>Q,]?S;,0F'K+630R7*+&6$HA2I,-)F0*U960@H"V1+DH)Y+;;3*@0^E)X
M'3C;?YRN)NE<1';;0CS2-)PLG8"43N(&2, D ^<#&=3?K_O^3;U@CVQ9B\NY
M-SL*"ABIB6G@25@DDI[<E<J2 ?&2&)P&SHW<WN^?OO9LVY9#R,>K7#0X?3MI
M641ZF.\IJ,L,H^!*G<I=>2A)45*2A/( '7.WIN.3=%W/HAEIJ<M24B*"0P4^
MF,*, ,<#Y$^#G&I'T@V#2].=H1?:A$MSJX3<+O6N0':213(P=F/(C.4&3QG&
MII:VIJ3LETM(VQET>*_NW8=8N)AU!("%R:.(\CS;<6@\K0E""B38.!(_F^,=
M)*4\"Q+/2T_3O;,M[K5C:^U\02BA/Q2HA'&$;[N 0Q( /C!Y.E_W7<KGU_W[
M'M6QM+%L[;]2'N=8O$=2R, P[P0&RW<L8_J\XYX@IK?7^?\ <UM@5D9R38W.
M0V;ECD=])2MYFLA/.ER982G/GVT-I"D16"1YJ"&D< 'BLK-:[EO:_!$::1ZN
M4S54[L0L498EAW<=N!PH&,<>!QIC]U;GVWT?V2I;T8HZ&C%/;*&(*LM74H@1
M%2,<L6<AG<CW+'V&K NY_=>/=O>O*KM@T5,^GMHT-N/F&05Y!EQEOH!D,!YG
ME:KB>XI3LA:%%4=HA"?Q%(%J[QW'2;5MM-M/;[YG5$2NGA'>P?@8[@">\L,L
M?O>.X^Y6+I3T_NG4W<57U-WU$[6YGFEMU/4\))VDE1VOD>A"G"#&"02/ )M$
M[8;G*KS1>N)^85TNKR!>-PF9L:: B4M,5!8BRG$'\:%2HK3+WBX//^9^(<_'
M5U;/J*VIV[;):]&2I-,G?WCM8XR 6'L2H#?KQI5.I=%:+?O?<--9)TGMR7"8
MTQBY102"R*1P>URPX. //TB1ZO.P3KWL*WC+:>;:EY/2QL(B *\'2_ED^/3?
MR@#Y$H;D+62D\@)\N>KFZ7VW\Y[SM4!0NL;-,Q X#0KZB,<<8+8!!X/CZZH7
MJ=7M0;0N#JX5Y6AA QW925PL@ /!)4G'CQX)QH<ST:>W*KW[G'<O77\3ZK'E
M=OM[@KJDH)2U-S^6W!9]I1 2ESZ&MGA'V4.04D)!Z8CK3?I;+'MY8<I))6P2
M2!6PK14SI-RH^$ ./..1QQR-4-TKL45[EO#2=K+'25* E<_',A52!SR#(S @
M ]P'L,:;CTP=D7':1ZB&,87E[KM9'N\GR+M^SAMU?M-B9.LE5E-)="OP>RG+
M*RED,.J/X8LE:TD(<5SO=2Z*'=G3HW&C3UI8HZ:LIW7XG3L13*P^8=>_@C S
M]!K5V!7S;:WO'2U3F.)ZF6FGC8%5(D#*.X^W865L8&<#5T_[0#O,XGVXX/H^
MMFAFSW+G%=86D9#B?-[#L#4+ZQ*@/Q!"LE5B;)'PE8*A\H\@:>Z#V%J_=$EV
M8 Q6> D @@"6<^D#XPV$9B<D8]]6OUJO0I;#%:T([KBRR,>X9"HP"@KYP2P;
M\$/;R-5EZ![19$[T;^Z[=$NL7_$6?Y-29SC3JFTE:L)T%DS#Q=;5XAQMJ=,_
MC[S4GX<B*9</*4MGJQ=Q;QSU:L=L4^G3VI:BFGPV%DFJ858# )!^&&$+QP7(
M&"1JN[/M7MZ9WFY.H:>LFIVB8H2RQ0R"-BA(!4,78,0 .Z+G.GI_9W-F"HVS
MW!ZEDOE2,JPW$\ZK&2H$>_BUO84%P^E/YEYG*,?2XH#Y;922?PCCE?E#4'?3
M6&Y%&S'+/%(RYQF=5)R/ RT)*_)2<<9UU^AEQ]*MO- SC,R1RJ" "3#A./J>
MYR0./!Q\BRGFFG6UMO)0XTXDH<:4 M"D%/!2I*AQP?(#@C@@GG[]*RK=F7R5
M*DG()X(.01C\?;W&F9*AU*, P(((( !&.0WT\_M]\:B_D6?]J/9KA[<2[N]:
M:6QA*WYD>J;77U3LEQ]];CTB-3Q$*LYQ=D+7[KC$5XI7R%%/VZ[U+0;@W-.B
M4T-;<I\*J=_>V%50J*"Y"KA0H !X S]=1VHK]N;8A8SRT=OC[F=D0(&+.Q9C
MA06RS%CG'DG/ SJ&V4>L+Z=]JBTQBVV:+JJGM/5<PKQ&XETTV+*267PY[T3^
M;"6A9#GFP0I)\N">!U,H.E._82M3%;)(9(NV966;LE4@Y&"".WQ[<^1J*574
MS9E0LM-+6&6-T9&#0@HP9?BSD\CDCQG0?NSYN#X7W6Y'>Z5N(UKKZCW+"R+7
MMI6!YIE=&UDL2TK$LI?;9>;#;14P6UH24A)0I)'QTVMM@KJW8HIKY1F&K:A,
M4T$F&8X3L#,P^\6'Q$\GXN3XTKM;-14VZ#/:Y@]*M8LL$R#L![I>X$+P!C/
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ME<M;&:^J183A#8'U]E*>?=+KZF&)"_-SD@>779IJ.^[AD2"E@JZ^4$*J+ZC
M8XP&/P\#CSCV!X.H_4UFW]NHTM1-1T*D%F([%=B3DM@?%R23C'&=0SR/UCO3
MY^IG4,S:?[XAN)<C2'X^+74RL?;=0MMW\3L1"G65(44K(94DI*AXD'@S2'I/
MOM DZ6J2)D*R#],J.I4@@87)S[8S^S&HM/U-V:X:&2N$T4B.A#(.U@>Y2"&(
MQD9/(R1]2," ]V\S547NBVE?Z N8-MK*?EL7+\(LJEN1%C14VK$"WFQX[+[+
M#T<PKYV<$-^TV(Z>$-@(0GIM=I4]R;9$5->X6BKTH9X:@3?$^4,RCN(^\60*
M^03G.3SG2N7V>VKNFHGM#AZ'[9$\#IW#"MZ;E5)R0%8E<#(!4X.#KZ"^C\EF
M9CJ#5V5V"?&;DVO<-R"8G[D2[C'JZPD$G@<DNR%DG@<DD](9=(E@N5="ARD=
M74JN!@=JS.% '&, #CVT[-GF>>U6Z:08>2CIF;/S:*/)X]R><_/0@_K^?Z[V
M*_[ L0_WTV)TU_0(D[8O!/\ K,O]W3Z5SK=_.>E^E*@_4&D T23Z6'^H#VO?
M[+ZO_P ]9]+SU)_GO?\ ^U1_\+!I@.G/\SK/_L5'_%SZJG]1NRE3>[/84.0K
MR9J*["(4+XX#<9_!L?LW$D@DE1ESY*T_ ^5)'SXCK\_^K<\LF_+O$Y#1TR6U
M(E(X DM5#*WU)+2,?<#CG7[$?DOT5/3='MN5<2 3W">^25)SDR/!N&ZTT7&,
M=HBB4'S[GYZ;?M)UI$V/N*I>OBEG#<$B2,ZS&:^ F-'JJ$?50FI"SPV$RK)#
M"%))Y<:8DIX("N.7T_LZ7"_Q25 Q06X2W&JDD.$PJL8X\GCF4G"\<#CQQW.N
MN[&VWLBIHZ!G:^;AFBM%IA@;]+)-4NJ3N ,MVQ1,6/ !# YXUXMK9/DG<WW
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M_)P^2"1P#@<9TL5GMFX>HEUFS42-&96DFED9_2CCSC 'MG^J//) \G5[&/\
M[/AV\0J,,9%M+9UO>_2E)LX;\"LBMR3\K6S 90MI38X(0VH\$!)5\GXI.7KU
MN9IY&AAITA)8(CY)"$L%#$9!.,#.?K@:N.'HG9HZ<+/53O,(_B9 I!;.2!GG
M R1R/GG0T7<OIRI[?.YW8>F*.UGWE3K[8#%#!M+)MIF=+CQIT12%R6X_\H/?
MS"DE'P>"?T/3);9OL^X]F4]WJU5)YZ+O=4![>[';D _T3C@>!QJ@+]:(K#N6
MHM<;/+'3U21H\B@$IG(R!Q[\M_CKZ ]8F0G0528@69!U3 4P6R?/W#BC11X?
MJLN<>/SSSP1TATI47^;OQV_G.1CG^TG\ !\A_ :=0 C;Z!,]PM:]N.23]FXS
M\_V<^_N=!=>EK*@Q/4NP%5^%+?D91LF-'6\XEMQNY?D6(9*U*X\E!U+GDD?B
M4O[#X/+@=3%<],$,7Q+]DI2<<CM"JWM[$DCY8X\<:5?8!0=0%,I"G[1-E?\
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M]@'=,.?]4C__ "<_\M>_0T?_ $*M/SJ1^Y1K)^NYV@Y1N'6^&[[U]42[N^U
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M?#;-V)023&*GND3(1_1,L(9T[CGC*]R@$<D@#'&.'UCLHN&VS<$3NGMTJDD
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MSJHZ*BH:FHJ)G[4187 'N2Q*^ .2<^V-7S7WNU6RF>JK*ZGBBAC+D^HK,YY
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ME3/&G;@MVJ[J"6SSC!)P<_KU=6XKM3V&QW*ZU,B0PT5#4S=S,%'=' Y0(2<
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MSZDK2RV#YN*!"4D@=?4<<DKE8T9RJ%R%!) !Y/'MCS\L<X]_.26.(=TCJ@)
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M5X7 XQC381HS\Q]N+$0Z])?=;:889;<=<?==6$H:90VE:U/*64H0VD%;A*0
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M^_C7&I)Y*&NW%;[375%QM"T-0SR/+ZI@84H=2CC$9+2GM!4<@D8/:-.QV?\
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MJ=Q(^TR,Y,I\95%1?F&U-D-(2D)3^$ < #CXX_3X^/\ #[?VXZL,*JXP ,#
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M1^FP:/O]-/6*$ #M,WJ%<<8QC P-3[9\]PGV_0R7-9%J\2(PF5UE[$GD6+U
M^7[_ $@F>[!!Y/).I2YI@6&;'H9N,YYB]%E^.V37M3Z+)*J%<5,M'W2)$">P
M^PYX*_$@E'DA?"TD* (X%)65=!.M315,U+4(05E@D:-^,\$CR.>1[C@Y'&NY
M6T%'<86IZZFAJH&!S%.BO&21C.",@_4$$>VJD]I^A?V.[!G3+2@I<XU5+F+>
M>7'U_DY33F0]RKR1391!R*)#:2I1*8U<8$= X0AM*.$BS[1UGWC:8_1$U-6\
M8:2KCD:8CY=RRK'[^\9]OPU6ETZ/;4N+-)&M31.Q)"TSH8U)Q@ 2(6[?IWC
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/:71HTNC1I=&C2Z-&O__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
